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PART I: SYNTHESIS OF 4’-O-GLYCOPYRANOSYL PAROMOMYCIN 
AMINOGLYCOSIDE ANTIBIOTICS: INFLUENCE OF THE GLYCOSIDE ON 
ANTIRIBOSOMAL, ANTIBACTERIAL ACTIVITY 
 
CHAPTER 1 
INTRODUCTION 
1.1 An Overview of Aminoglycoside Antibiotics(AGAs) 
Since the discovery of the first naturally produced antibiotic Penicillin, 
various types of antibiotics have emerged, either from natural sources or 
synthetic routes. Generally, antibiotics can be classified into four types according 
to their acting mechanism: cell wall synthesis inhibitors; protein synthesis 
inhibitors; oligonucleotides replication and repair inhibitors; and folate coenzyme 
biosynthesis inhibitors.1 Among them, aminoglycosides antibiotics (AGAs) are an 
old family of antibiotics, which target protein synthesis. They have been 
developed for around 70 years since the introduction of streptomycin in 1944. 
Early AGAs like neomycin, paromomycin (Figure 1) and gentamicin were used to 
treat Gram-negative and most Gram-positive bacterial infections effectively. The 
widely adopted resistance of bacteria towards AGAs drove the birth of a second 
generation of AGAs, the semisynthetic derivatives netilmicin (1976) etc. However, 
the toxicity limitations of those AGAs eventually led to their replacement by other 
broad spectrum antibiotics with fewer side effects, fluoroquinolones for example.2  
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Figure 1. Examples of AGAs: paromomycin 1 and apramycin 2 !
1.2 AGAs Mechanism of Action 
AGAs bind to bacterial 16S rRNA helix 44. The binding site is part of the 
aminoacyl-tRNA acceptor site, which is commonly called A site (Figure 2).3 Even 
though AGAs all effectively inhibit elongation step in protein translation, their 
actions are mechanistically different4. They affect protein synthesis either by 
inducing miscoding or by inhibiting translocation of the tRNA-mRNA complex.3 
Paromomycin and apramycin represent two distinct mechanisms of action. 
Apramycin acts primarily by blocking the translocation of ribosome along mRNA 
while only limited codon misreading is observed. Paromomycin, however, 
destacks A1492 and A1493 and causes significant miscoding .4 
In the absence of paromomycin, energy is required to flip out A1492 and 
A1493 so they can contact with tRNA. However, paromomycin ring I forms so 
tight hydrogen bond with the phosphate backbone of A1493 that it locks the 
! 3!
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structure in the flipped-out form. As a result, the energetic cost of both cognate 
and non-cognate tRNA binding is reduced. An undifferentiated affinity of the A-
site for cognate and non-cognate tRNA is resulted and codon misreading takes 
place (Figure 2).5 
 
 !
Figure 2: Paromomcyin interacting with bacterial 30S subunit. [This figure 
has been reproduced from “Perez-Fernandez, D.; Shcherbakov, D.; Matt, T.; 
Leong, N. C.; Kudyba, I.; Duscha, S.; Boukari, H.; Patak, R.; Dubbaka, S. R.; 
Lang, K.; Meyer, M.; Akbergenov, R.; Freihofer, P.; Vaddi, S.; Thommes, P.; 
Ramakrishnan, V.; Vasella, A.; Bottger, E. C. Nat. Commun. 2014, 5, 4112/1”.] 
 
1.3 Paromomycin Interactions With 30S Ribosomal Subunit 
Paromomycin is an efficient antibiotic against Gram-negative and many 
Gram-positive bacteria. It is not used as an antibiotic anymore due to its toxicity, 
but nevertheless paromomycin was licensed in India as an effective, well 
tolerated treatment for Visceral Leishmaniasis (VL) in 2007.6 Understanding the 
! 4!
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interactions between paromomycin with the decoding A site of bacterial ribosome 
is of great significance as it provides the basis for rational drug design.7 A 
crystallographic structure gives insight into how paromomycin docks into the 
major groove of Helix44 (Figure 2).8,9 
Paromomycin ring IV and ring II contact the backbone of both sides of H44. 
Additionally, ring II also tightly binds to basesFigure 2). Ring III only weakly 
binds to the rRNA. The binding model of ring I is very interesting and the most 
important one. It behaves like a nucleotide base, stacking against G1491 and 
hydrogen-bonding with A1408. The base at position 1408 of 16S rRNA is critical 
to determine the aminoglycosides selectivity.9 Drug-susceptible bacterial 
ribosomes are characterized by an adenine at position 1408, while drug resistant 
eukaryotic cytoplasmic ribosomes is conferred by a guanine at the homologous 
position.7,10 This is one of the most important reasons why we are interested in 
modifying ring I of paromomycin. 
 
1.4 Selectivity and Ototoxicity 
The selectivity of aminoglycoside derives from the fact that the decoding 
sites of rRNA small ribosomal subunits of bacteria and humans have minor 
sequence differences, as illustrated in Figure 3.3 The decoding A site of wild type 
bacterial 16S rRNA is shown in Figure 3A as shadow region. Figure 3B illustrates 
the homologous 18S rRNA sequence in human cytosolic ribosomes. Figure 3C is 
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homologous 12S rRNA sequence in human mitoribosomes. Figure 4D shows 
homolgous 12S rRNA sequence in human mitoribosomes with a single mutation 
of A1555G, which confers to hyper-susceptibility to AGAs induced ototoxicity.3 
Aminoglycosides are able to bind more strongly to the Prokaryotic 
ribosome than the Eukaryotic ribosome. On the other hand, the sequence 
difference at the decoding site is so minimal that competing binding of 
aminoglycosides to human ribosome is expected. Therefore, the toxicity and 
selectivity are intertwined together making it very challenging to modify AGAs to 
meet clinical requirements.11 
As aminoglycosides began to be used widely in clinics after 1950, the 
adverse effects became obvious. Among them, nephrotoxicity and ototoxicity are 
the major obstacles limiting the use of this type of antibiotics. Nephrotoxicity is 
resulted from accumulation of AGAs in the renal cortex tissue.11,12 Clinically 
people are using a large dose strategy to minimize this side effect. When a large 
dose of AGAs is applied within the clinical meaningful range, kidneys can only 
absorb limited amount of AGAs.13,14 In contrast, ototoxicity of aminoglycosides is 
mostly irreversible. The hearing loss results from degeneration of hair cells and 
neurons in the cochlea.11 AGAs induced deafness is also affected by genetic 
factors. For example, individuals with a single mutation A1555G in the A-site of 
the mitoribosomal small subunit are hyper-susceptible to ototoxicity.15  
! 6!
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Figure 3. Comparison of prokaryotic and eukaryotic ribosomal decoding 
site rRNA sequences.3 
 
1.5 Renaissance of Aminoglycosides 
Due to the toxicity of aminoglycosides, widely adopted bacterial resistance 
and the emergence of other broad spectrum antibiotics with less side effects 
(fluoroquinolones etc.), interest in improving the pharmacological profile of AGAs 
declined in the late 1970s.2 However, all other common antibiotics have been 
encountered increasing resistance from bacteria. At the same time, limited 
biological targets in bacterial metabolism make it difficult to find new types of 
antibiotics. Therefore, there is a revived interest in modifying aminoglycosides.2 
Previously researchers were trapped by the lack of efficient genetic tools to 
study the interaction between eukaryotic rRNA with aminoglycosides. This hurdle 
has been overcome with the pioneering work of Böttger et. al. by engineering the 
rRNA decoding site of eukaryotic ribosome in bacteria. They replaced the 
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bacterial ribosomal A site with its eukaryotic counterpart, resulting in bacterial 
hybrid ribosomes with a fully functional eukaryotic rRNA decoding site (Figure 
3E-3G).3,16 This technique allows the fast screening of aminoglycosides 
derivatives in vitro to evaluate their potential ototoxicity. It is also one of the key 
techniques in this collaborative project with the Böttger group. Genetic analysis 
identified mitoribosome as the target in AGAs induced ototoxicity.17 This proposal 
is further supported by the finding that antibacterial activity of 4-monosubstituted 
2-deoxystreptamine apramycin 23 can be separated from aminoglycosides 
ototoxicity. Recent published data demonstrated that modifications of 
paromomycin at the 4’ position reduce anti mitoribosomal activity but retain its 
antibiotic activity.9  
 
1.6 Recent Efforts to Improve AGAs Pharmaceutical Profile  
Various modifications of paromomycin at C(4’), C(6’), C(5”), C(6’”) positions 
had been screened for activity and selectivity.8,10,18,19 Work done by the Vasella 
and Böttger groups revealed that 4’-O-alkyl, and 4’,6’-O-alkylidene paromomycin 
derivatives retain strong antibacterial activity comparable with paromomycin 
against Staphylococcus aureus and of E. coli.9 They showed minimal affinity to 
the hybrid human mitochondrial ribosomes carrying the A1555G or C1494U 
alleles, which are hyper-susceptible to AGA-induced hearing loss. 4’-O-(3-
phenylpropyl) paromomycin ether 3, the 4’,6’-O-benzylidene paramomycin acetal 
! 8!
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4, and the 4’,6’-O-(3-phenypropylidene) paromomycin acetal 5 are shown here in 
Figure 4 to exemplify these two series.9 
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Figure 4. Potential paromomycin derivatives 
   
Crystallographic studies identify the same binding patterns between the 
bacterial decoding site and these derivatives to paromomycin itself. The 
chemically introduced 4’-O-substituents of paromomcyin derivatives extend out of 
the binding pocket and extrude to approach the flipped out base A1492 (Figure 
5B). An overlay of the X-ray crystal structures of apramycin 2 and 4’,6’-O-
modified paromomycin 4 (Figure 5C) display the common binding mode between 
the two. Most importantly, the 4’,6’-modified paromomycin derivative can 
discriminate bacterial ribosome from hybrid mitoribosome A1555G which confers 
hyper-susceptibility to ototoxicity. These results identify the C4’ position as a 
promising site to increase the selectivity of paromomycin derivatives via the 
manipulation of drug-target interaction.3 
! 9!
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Figure 5. X-Ray crystal structure of the bacterial decoding A site 
intereacting with A) apramycin; B) 4’,6’-O-benzylidene paromomycin acetal; 
and C) an overlay of A and B.[This figure has be reproduced from “Perez-
Fernandez, D.; Shcherbakov, D.; Matt, T.; Leong, N. C.; Kudyba, I.; Duscha, S.; 
Boukari, H.; Patak, R.; Dubbaka, S. R.; Lang, K.; Meyer, M.; Akbergenov, R.; 
Freihofer, P.; Vaddi, S.; Thommes, P.; Ramakrishnan, V.; Vasella, A.; Bottger, E. 
C. Nat. Commun. 2014, 5, 4112/1”. ] 
 
The above studies lead to the hypothesis that the substituent at the 4’ 
position possibly exerts its influence over binding either by interacting with the 
zone of organized water into which it projects, or through the stabilization of the 
flipped out conformations. Therefore, the goal of this project is to synthesize 
series of 4’-O-glycosylated derivatives of paromomycin mimicking the 
aminoglucosyl ring of apramycin in order to improve selectivity and diminish 
toxicity.  
! 10!
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CHAPTER 2 
4’-O-GLYCOSYL PAROMOMYCIN SYNTHESIS AND BIOLOGICAL RESULTS 
2.1 Results and Discussion 
  2.1.1 4’-O-Glycosyl Paromomycin Synthesis 
    2.1.1.1 Synthesis of 4’-O-Glycosyl Paromomycin Intermediate  
Pentaazido-paromomycin 8 was prepared from paromomycin monosulfate 7 
by diazo transfer20 from imidazole-1-sulfonyl azide hydrochloride (Stick’s reagent, 
6) in the presence of an excess amount of K2CO3 and a catalytic amount of 
CuSO4 (Scheme 2).21 Stick’s reagent can be conveniently prepared on a large 
scale from cheap starting materials. It is shelf-stable and easily recrystallizes 
from ethyl acetate under acidic conditons (Scheme 1).21 
NaN3
i) SO2Cl2, MeCN
ii)imidazole
N3 S
O
O
N N iii) HCl in EtOH N3 S
O
O
N N
6
HCl
 
Scheme 1. Stick's reagent synthesis !
As a cheap replacement of triflyl azide, Stick’s reagent also showed higher 
efficiency in this diazotransfer reaction to paromomycin: the yield increased from 
49%10 to 63%. Regioselective protection of the 4’-OH and 6’-OH groups with 
benzylidene acetal gave 9. The remaining free hydroxyl groups were O-
benzylated with benzyl bromide (BnBr) in the presence of sodium hydride (NaH) 
in THF to yield 10. Regioselective reductive cleavage of the benzylidene acetal of 
! 11!
!
10 with NaCNBH3 in the presence of 2 M HCl22,23 left the 4’ hydroxyl group of 
compound 11 open for further modification (Scheme 2).10 
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Scheme 2. Synthesis of a selectively protected paromomycin acceptor !
    2.1.1.2 Glycosylation Reactions 
             After the intermediate 11 was obtained, it was glycosylated with a series 
of known monosaccharyl donors (Scheme 3).24-26 
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Scheme 3. Glycosylation 
 
Thioglycosides donors (12-15) were preactivated with DPSO/Tf2O (DPSO: 
diphenyl sulfoxide)27 at -72 °C in the presence of 2,4,6-tri-tert-butylpyrimidine 
(TTBP)28 as a mild, hindered, non-nucleophilic base. Subsequent addition of 
paromomycin acceptor provided the glycosides as α- and β- mixtures. As it is 
evident from the results, except for the formation of mannopyranoside 17, all 
glycopyranoside formations were characterized by a α-selectivity, which is 
consistent with the previous reports (Table 1).29-31 The attention was focused on 
the study of the antibiotic profile of both α and β-isomers. The α and β-isomers 
were separated by regular liquid chromatography first, and then by reverse phase 
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high pressure liquid chromatography. The yields and anomeric ratios of each 
glycosylation are indicated in Table 1.  
  
    2.1.1.3 Deprotection 
Extensive exploration of the direct hydrogenolysis of benzyl ethers and azide 
groups with Pd(OH)2/C (20% wt.) in various solvents was made. It identified 
methanol/water solvent system with a certain amount of acetic acid as the best 
solvent system. However, the one step deprotection was not reproducible and 
suffered low yield. Therefore, a stepwise sequential deprotection of azide groups 
using the Staudinger reaction followed by the deprotection of benzyl ether groups 
on hydrogenolysis was adopted (Scheme 4). In a small scale deprotection of 
these paromomycin derivatives, the amine groups would undergo condensation 
with the formaldehyde impurity within methanol solvent to form imine, which 
could be reduced by hydrogenolysis to methylamine compounds, as identified by 
high resolution mass spectrometry. The yields of the Staudinger reaction and the 
hydrogenolysis reaction are also included in Table 1.  
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Scheme 4. Deprotection!
 
 
Entry 
 
Donor  
 
Glycosylation  
yield, ratio 
Staudinger 
reaction 
yield 
Hydrogenolysis 
yield 
1 12 
 
16, 42%, α:β = 3.2:1 20α, 64% 24α, 39% 
2 20β, 55%      24β, 87% 
3 13 
 
17, 51%, α:β = 1:3.6 21α, 91% 25α, 33% 
4 21β, 66% 25β, 25% 
5 14 
 
18, 60%, α:β = 6.4:1 22α, 81% 26α, 62% 
6 22β, 78% 26β, 39% 
7 15 
 
19, 50%, α:β = 4.5:1 23α, 64% 27α, 64% 
8 23β, 48% 27β, 29% 
Table 1.  Synthesis of 4’-O-glycosyl paromomycin derivatives. 
 
  2.1.2 Antiribosomal Activity 
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    2.1.2.1 Anti Bacterial Ribosomal Activity 
      2.1.2.1.1 Anti Wild Type Bacterial Ribosomal Decoding A Site Activity 
To access the interaction between the synthesized paromomycin derivatives 
and bacteria 16S rRNA A site, cell-free translation assays were conducted. 
Compound antiribosomal activity in the translation inhibiting assay is defined as 
the concentration to inhibit the in vitro translation reaction by 50% (inhibitory 
concentration, IC50)9,32. IC50 values of all compounds are in µg/ml. Paromomycin 
1, apramycin 2, and the 4’-paromomycin derivatives 3 and 5 were also tested as 
comparators to the 4’-O-glycosyl paromomycin derivatives synthesized. As 
shown in Table 2, with the exceptions of 4’-O-4-amino-α-D-glucopyranosyl 
paromomycin 27α, all the paromomycin derivatives synthesized 24-27 showed 
significant increase of IC50 toward wild type bacterial ribosome, compared to 
paromomycin itself. If compare the IC50 values of the corresponding α, β-glycosyl 
paromomycin carefully, it is clear that both anomers of 4’-O-D-glucopyranosyl 
paromomycin 24 and 4’-O-D-manno pyranosyl paromomycin 25 showed similar 
activity to inhibit cell-free translation, while a significant IC50 difference of two 
times or more existing between the α, β anomers of other glycosyl paromomycin 
derivatives. A close scrutiny of the data between anomers revealed something 
even more interesting. While the α anomers of 4’-O-D-galactopyranosyl 
paromomycin 26 and 4’-O-4-amino-D-glucopyranosyl paromomycin 27 showed 
much stronger anti wild-type ribosome activity than the corresponding β anomers. 
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 Bacterial A Site 
Cmpd 
Wild 
Type 
G1491C G1491A A1408G 
1 0.03±0.02 10.42±2.86 0.57±0.09 0.26±0.04 
2 0.06±0.04 31.21±7.27 5.00±1.36 128.89±41.49 
3 0.20±0.07 210.73±39.98 51.26±15.72 14.52±8.60 
5 0.10±0.03 124.07±0.03 43.01±11.31 3.81±2.44 
24α 0.32±0.05 109.01±33.61 27.08±10.41 21.84±6.87 
24β  0.37±0.06 294.83±21.70 15.50±2.72 9.32±1.36 
25α 0.29±0.03 81.32±50.80 8.79±0.12 5.10±0.78 
25β  0.46±0.02 297.39±21.16 51.48±17.39 27.91±2.04 
26α 0.55±0.08 118.67±8.58 18.68±2.37 12.01±1.17 
26β  1.52±0.30 623.16±46.00 78.05±2.35 36.46±2.23 
27α 0.12±0.04 32.79±2.05 6.07±0.06 7.06±0.52 
27β  0.29±0.07 32.03±2.21 4.87±0.46 2.39±0.21 
Table 2. Compound interaction with polymorphic residues in the drug 
binding pocket (IC50, µg/ml)a 
a)  All measurements were made in triplicate for compounds 1, 2, 3, 5, 24-27. 
 
  4’-O-4-Amino-D-glucopyranosyl paromomycin 27 has greater inhibiting 
activity than other paromomycin derivatives 24-26, which also have a 6-carbon 
monosaccharyl substituent at 4’ position. This may be resulting from the 
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increased electrostatic attraction between the positively charged paromomycin 
derivatives and negatively charged ribosome33-35 caused by the extra amino 
group. To be more specific, as mentioned before in the crystal structure of 
paromomycin interacting with bacterial A site, additional hydrogen bonds link the 
hydroxyl groups at positions 3’ and 4’ to the phosphate groups of the two adenine 
bases 1492 and 1493, helping to stabilize the position of ring I (Figure 6). The 
positively charged amine group in 4-amino-D-glucopyranoside probably 
increased the affinity of the paromomycin derivative to the ribosome via 
interacting with the negatively charged phosphate groups in A1492 and A1493 
nearby.9 As shown in Figure 6, the 4’-OH group forms a hydrogen bond with the 
phosphate backbone of A1493, suggesting if the hydrogen bond is diminished, a 
weaker binding would be resulted. But 4’-deoxyparomomycin only showed 
minimal loss of inhibiting activity.10,36 It seems that the hydrogen bonding 
between the 4’-OH and the phosphate backbone does not affect considerably the 
binding affinity. However, in this study, most of the 4’-glycosyl paromomycin 
derivatives suffered significant loss of binding acitivity.  
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                        !
            Figure 6. Paramomycin ring I interaction with bacterial A site 
[This figure has been reproduced from “Perez-Fernandez, D.; Shcherbakov, D.; 
Matt, T.; Leong, N. C.; Kudyba, I.; Duscha, S.; Boukari, H.; Patak, R.; Dubbaka, S. 
R.; Lang, K.; Meyer, M.; Akbergenov, R.; Freihofer, P.; Vaddi, S.; Thommes, P.; 
Ramakrishnan, V.; Vasella, A.; Bottger, E. C. Nat. Commun. 2014, 5, 4112/1”.] !
This phenomena probably can be explained by the weakened CH-π 
stacking between paromomycin ring I and G1491 at the bottom of the binding 
pocket.37,38 Ring I fits into the binding pocket well mostly by stacking interactions 
with G1491 and hydrogen bonds with A1408.9 Weakened CH-π interaction may 
be caused by three factors. The first factor is the reduced electron density in C4’-
H bond. Alkylation of O4’, would lower the electron density at this position, thus 
reduce the electron density at C4’. The electron density would be further reduced 
from an acetal linkage (compound 5) or a glycosidic bond (compounds 24-27) at 
this position. Another factor is the increased steric hindrance resulting from the 
4’-O substituent. It also may explain the different activities between α, β anomers. 
The third factor is to which degree the 4’-O pyranoside disturb the solvent shell 
surrounding the binding site. X-ray crystallographic studies of aparamycin 2, 4’,6’-
O-benzylidene paramomycin acetal 3 revealed a common binding pattern at the 
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bacterial A site as shown in figure 5.9  The aminoglucosyl residue of apramycin 
and the 4’-substituent of compounds 3 both extend into the solvent shell between 
A1492 and G1491. If the 4’-glycosyl paromomycin derivatives adopt the same 
binding pattern, to which extent the 4’-substituent fits well into this kind of 
hydrophilic environment, which is composed of organized water molecules, it 
would affect the stability of the binding pattern as a whole. Studies showed that 
mannopyranosides, glucopyranosides have less affinity to water molecules 
compared to galactopyranosides. Therefore, they can fit better into the organized 
water and disrupt the hydrophilic environment less than galactopyranosides.39-42 
As a result, the galactosyl derivatives 26α,β showed least inhibiting activity 
compared to other pyranosyl derivatives. Mannosyl derivatives 24α,β and 
glucosyl derivatives 25α,β had similar anti-ribosomal activity to each other as it 
can be explained by their similar affinity to water.  
 
      2.1.2.1.2 Anti Mutant Bacterial Ribosomal Decoding A Site Activity 
Structurally, in the binding pocket two slightly different bases—residues 
1408 and 1491 determine the selectivity of AGAs. Residue 1408 is an adenine in 
bacterial binding site and in mitochondrial ribosomal binding site. It is a guanine 
in cytosolic ribosomal binding site. Residue 1491 is a guanine in bacterial binding 
site, but an adenine in cytosolic ribosomal binding pocket, and a cytosine in 
mitochondrial ribosomal binding pocket. Other than that, the bases within the 
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binding pockets are the same (Figure 3). So it is important to understand how a 
single allelic residue change could subtly affect the binding of AGAs. Therefore, 
the 4’-glycosyl paromomycin derivatives were assayed for their ability to inhibit 
three ribosomes with single mutation as shown in table 2. G1491C stands for the 
1491G at the bacterial decoding A site was replaced by a cytosine found in 
human mitochondrial rRNA. G1491A stands for the 1491G at the bacterial 
decoding A site was replaced by an adenine found in human cytosolic rRNA. 
A1408G stands for the 1408A at the bacterial decoding A site was replaced by a 
guanine found in human cytosolic rRNA.3 
Data in table 2 illustrate that all of the compounds tested showed 
significant loss of inhibiting ability against the three mutant ribosomes compared 
to the wild type ribosome. This loss implies a disruption of the binding mode as a 
result of a single base change at the binding pocket. More importantly, it seems 
the G1491C mutant ribosome endures greater loss of binding affinity to 
paromomycin derivatives than G1491A. One possible explanation is that adenine 
has similar structure to guanine, which has two conjugated π rings. 1491 base is 
at the bottom of the binding pocket, providing CH-π interaction to stabilize 
paromomycin ring I inside the bacterial A site. Both, adenine and guanine have 
big π system to support the strong CH-π stacking, while on the other side, 
cytosine only has one aromatic ring. Another possible explanation is that in the 
wild type ribosome, there is a strong base pair between C1409 and G1491 to 
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make a tighter binding pocket, but in G1491C and G1491A mutants, this base 
pair bonding has been diminished. A1491 is still able to form a pseudobase 
interaction with C1409 by N6, N1of adenine donating hydrogen bond to N3 and 
the carbonyl group of cytosine, though not as strong as G1491. But C1491 is not 
able to form this kind of pseudobase interaction. Therefore, a looser binding 
pocket in G1491C mutant has been formed, leading to weaker affinity to 
paromomycin derivatives.  
All of the compounds experienced loss of activity towards the A1408G 
mutant ribosome. In wild type ribosome, ring I of paromomycin forms a pseudo 
base-pair interaction with adenine 1408. N6 of adenine donates a hydrogen to 
ring oxygen of ring I. The 6’–OH donates a hydrogen to the N1 of adenine (Figure 
6)9. In A1408G mutant, an alternative similar pseudobase interaction with 
paromomycin is possible according to the modeling study.43 Nevertheless, the 
lower anti A1408G ribosomal activity was observed across paramomycin, 
apramycin and all the paramomycin derivatives shown in table 2 suggesting that 
such an alternative pseudobase pair is weaker than the original one. If the 6’-OH 
group forms inter-residue hydrogen bonds with the 4’-O-glycosyl ring, it can 
reduce the availability for 6’-OH to form a hydrogen bond with 1408 adenine. 
That is another possible reason for the lower activity of paromomycin derivatives 
against wild type bacterial decoding A site. In the case of A1408G mutant, such 
guanine-ring I pseudobase interaction is even weakened in the binding with 4’-O-
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glycosyl paromomycin.  
When comparing the anti ribosomal activity of α, β anomers, it is clear that 
with the exception of 4’-O-4-amino-α-D-glucopyranosyl paromomycin 27, 
compounds 24-26 all showed a similar pattern that β anomers inhibit the 
translation function of those mutant ribosomes much less than the corresponding 
α anomers. α, β isomers of 4’-O-4-amino-α-D-glucopyranosyl paromomycin 27 
have similar anti mutant ribosome activity to each other.  
  
    2.1.2.2 Anti Hybrid Ribosomal Activity 
As mentioned before, ototoxicity is the major hurdle for paromomycin 
derivatives to overcome. Recent advances showed a strong correlation between 
the aminoglycoside-induced ototoxicity and aminoglycoside-induced dysfunction 
of the mitochondrial ribosome. There are two groups of people hyper-susceptible 
to AGA-induced ototoxicity—one with A1555G mutation in their mitochondrial 
ribosome decoding site, another with C1494U mutation.9,44,45 In order to access 
the probability of the synthesized paromomycin derivatives to induce deafness, 
their activity against hybrid wild type mitochondrial ribosome and mutant A1555G 
ribosome was tested (Table 3). To create the hybrid ribosome, complete 
eukaryotic decoding A site was inserted into the bacterial ribosome.16 
In a general way as shown in Table 3, the eukaryotic ribosomes, whether 
it is wild type mitochondrial ribosome, A1555G mutant ribosome or cytosolic 
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ribosome, all endure less translation function loss than the bacterial decoding 
ribosome. 4’,6’-O-phenylpropylidene paromomycin acetal 5 stands out as the 
most selective paromomycin derivative to avoid ototoxicity as demonstrates its 
big IC50 value towards both wild type mitochondrial ribosome and A1555G 
mutant ribosome. While paromomycin itself can inhibit the translation of A1555G 
mutant ribosome much stronger than the wild type mitochondrial ribosome, that is 
not the case for all of its 4’-O modified derivatives. That is especially obvious for 
24α, 25α, 26α, 27α, which showed much less activity against A1555G mutant 
than wild type mitochondrial ribosome. It suggests that the 4’-O-glycosyl 
paromomycin provides a promising modification pattern to reduce the hearing 
loss within the group hyper-susceptible to the AGA-induced ototoxicity.  
In wild type mitochondrial ribosome A site, there are two non-Watson-
Crick base pairs at the bottom of the binding pocket: 1493C!1556C, 
1494C!1555A. In the mutant mitochondrial ribosome A site, one of the non-
Watson-Crick base pairs has been replaced with a strong Watson-Crick base pair 
of 1494CΞ1555G. This results in a more rigid binding pocket within the mutant 
ribosome. Presumably, 4’-O-substituents fit less into the mutant decoding site, 
thus affect the translation function less. Noteworthy, 4’-O-4-amino-D-
glucopyranosyl paromomycin has stronger activity against wild type bacterial 
decoding A site, but it also shows stronger activity against both mitochondrial wild 
type ribosome and also A1555G mutant. It seems the introduction of an extra 
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amine group provides more hydrogen bond to the ribosomes, but it binds 
unselectively. 4-amino-D-glucopyranosyl paromomycin does not show much 
differentiation between the various ribosomes tested.  
 
 Bacterial 
A site  
Eukaryotic A site 
Compound Wild Type Mitochondrial 
Wild Type 
Mitochondrial 
A1555G 
Cyt 14 
1 0.03±0.02 50.54±13.04 5.83±2.27 10.39±2.57 
2 0.06±0.04 58.03±18.80 26.06±7.08 49.17±26.01 
3 0.20±0.07 49.85±15.39 105.68±39.23 268.57±54.97 
5 0.10±0.03 330.74±115.30 126.88±54.36 183.86±84.90 
24α 0.32±0.05 1.86±0.36 13.98±2.56 46.26±4.65 
24β  0.37±0.06 59.12±6.57 83.64±24.45 117.53±29.68 
25α 0.29±0.03 2.19±0.07 18.05±4.68 51.72±16.80 
25β  0.46±0.02 54.60±8.3 85.70±27.23 90.35±26.69 
26α 0.55±0.08 2.23±0.33 14.95±0.11 35.63±2.23 
26β  1.52±0.30 141.35±3.08 209.22±52.33 286.76±32.27 
27α 0.12±0.04 0.34±0.01 3.62±1.22 18.95±5.37 
27β  0.29±0.07 7.62±3.30 17.38±5.12 21.43±8.53 
Table 3. Compound interaction with hybrid ribosomes (IC50, µg/ml)a 
a) All measurements were made in triplicate for compounds 1, 2, 3, 5, 36-39 
 
In table 4, the selectivity of drugs toward eukaryotic ribosomes against 
bacterial ribosome is measured as a ratio between their absolute IC50 values. 
The relative activity values can better reflect the selectivity of those compounds. 
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The bigger the relative values are, the more selective they are. When α, β 
anomers are compared, it is clear that β anomers of compounds 24-27 inhibit the 
function of both, mitochondrial wild type ribosome and mutant A1555G ribosome 
much less than their corresponding α anomers as evident in Table 4. It seems 
that the equatorial orientation of the glycosidic bond at the 4’-glycosyl ring would 
increase the selectivity of paromomycin derivatives towards bacterial decoding A 
site. This kind of equatorially oriented modification at 4’ position should bring less 
ototoxicity.  
The cytosolic 14 hybrid ribosome (Cyt 14) cell-free translation was also 
tested in the presence of paromomycin derivatives. The ribosome carries the A 
site of human cytosolic rRNA, incorporating both of the G1491A and A1408G 
single point mutations. The test stands for general toxicity, because cytosolic 
ribosomes are widely spread in the cytosol and are responsible for translating 
most proteins of the cells. Aside from that, AGAs does not need to go through the 
two-layered membrane of mitochondria to bind cytosolic ribosomes. All the 
compounds tested showed less antiribosomal activity towards the Cyt 14 hybrid 
than towards the bacterial wild type. Noteworthy, 4’-O-4-amino-D-glucopyranosyl 
paromomycin 27 even exhibited little selectivity towards Cyt14 hybrid ribosome. 
This further proves the previous hypothesis that 4-amino-D-glucopyranosyl 
paromomycin binds to the ribosome binding pocket unselectively, and are not 
able to differentiate the subtle structural differences between ribosomes. 
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 Bacterial 
A site  
Eukaryotic A site 
Compound Wild 
Type 
Mit13/Smsb A1555G/Smsc Cyt14/Smsd 
1 0.03±0.02 1684.67 194.33 346.33 
2 0.06±0.04 967.17 434.33 819.50 
3 0.20±0.07 249.25 528.40 1342.85 
5 0.10±0.03 3307.40 1268.80 1838.60 
24α 0.32±0.05 5.81 43.69 144.56 
24β  0.37±0.06 159.78 226.05 317.65 
25α 0.29±0.03 7.55 62.24 178.34 
25β  0.46±0.02 118.70 186.30 196.41 
26α 0.55±0.08 4.05 27.18 64.78 
26β  1.52±0.30 92.99 137.64 188.66 
27α 0.12±0.04 2.83 30.17 157.92 
27β  0.29±0.07 26.28 59.93 73.90 
Table 4. Compound selectivity toward eukaryotic A site over bacterial A 
sitea 
a) All measurements were made in triplicate for compounds 1, 2, 3, 5, 36-39; 
b) Cyt14/Sms: human cytosolic ribosome IC50 divided by wild type bacterial 
decoding A site IC50; 
c) Mit13/Sms: human mitochondrial ribosome IC50 divided by wild type bacterial 
decoding A site IC50;  
d) 1555G/Sms: human mitochondrial ribosome with mutation A1555G IC50 
divided by wild type bacterial decoding A site IC50. 
 
2.1.2.3 Antibacterial Activity 
All the paromomycin derivatives along with paromomycin 1 and apramycin 2 
were accessed for their activity against clinical isolates of Staphylococcus aureus 
and Escherichia coli (Table 5).  Their antibacterial activity was evaluated by the 
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determination of Minimal Inhibitory Concentration (MIC, µg/ml). The results of 
these studies are indicated in the table 5 below. 
Aside from AG 039 and AG 042, all the other strains are less resistant to 
the paromomycin derivatives than paromomycin with the exception of 4’-O-4-
amino-α-D-glucopyranosyl paromomycin. It is consistent with the result obtained 
from anti wild type bacterial decoding A site activity. Generally, α anomers can 
inhibit the growth of the strains better than β amomers. It is also consistent with 
the data from anti wild type bacterial decoding A site activity. The consistency in 
these results further proved that the cell-free translation assay is a fast and 
reliable model to evaluate the activity of AGAs to inhibit bacteria growth. Strains 
AG 039 and AG042 achieve their resistance toward AGAs through 
phosphorylation at 3’ or 4’ position at AGAs.46,47 4’-modified paromomycin 
derivatives block the possible phosphorylation at 4’ position. As a result, there is 
a broadly weaker resistance of the two strains to paramomycin derivatives, 
especially in the case of compounds 3, 5, 24α and 27α. 
 
 
 
 
Compound 
Strain 
Staphylococcus aureus 
(MRSA) 
Escherichia coli 
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 AG 
038 
AG 
039 
AG 
042 
AG 
044 
AG 
006 
AG 
001 
AG 
055 
AG 
003 1 4 >256 >256 4-8 2-4 16-32 8 8-16 
2 8 8 8 16 4 16 8 8-16 
3 2-4 8 4 4-8 8 16 16 8-16 
5 4-8 8 4-8 16 16-32 32-64 32 32 
24α 32 32 32 16-32 16-32 128 128 128 
24β  128 ≥128 >128 128 32 >128 >128 >128 
25α 64 ≥128 >128 32-64 16 >128 >128 ≥128 
25β  ≥128 ≥128 ≥128 ≥128 64 >128 >128 >128 
26α 64 128 64 64 32 >128 >128 >128 
26β  ≥128 ≥128 >128 >128 128 >128 >128 >128 
27α 4 8-16 8-16 4 2-4 32 32 16-32 
27β  32 >64 >64 32 16 >64 >64 >64 
Table 5.  Minimal inhibitory concentrations (MIC, µg/ml) of clinical isolates 
 
2.2 Conclusion 
A series of 4’-O-glycopyranosyl paromomycin have been synthesized. The α 
and β anomers of these analogs were tested individually for their ability to inhibit 
cell-free translation from both, bacterial ribosomes and hybrid bacterial 
ribosomes with eukaryotic decoding A site. All paromomycin derivatives 
synthesized (compounds 24-27) suffered significant loss of anti wild type 
bacterial ribosome activity, compared to their parental paromomycin. All the 
paromomycin analogues synthesized showed less ability to inhibit the translation 
of both mutant bacterial ribosomes and hybrid bacterial ribosomes than the 
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original wild type bacterial ribosome. In the study of anti hybrid ribosome activity 
assays, it is clear that 4’-O-glycosyl paromomycin derivatives with equatorially 
oriented glycosidic bonds at the 4’-O-glycosyl ring has more selectivity toward 
mitochondrial hybrid ribosomes than their corresponding derivatives with axially 
oriented glycosidic bonds. As AGAs induced ototoxicity is believed to be 
associated with the anti mitoribosome activity, it implies future modification at 4’-
O position can rely on introducing equatorially positioned substituents to improve 
selectivity of the antibotics. 
Among all the paromomycin derivatives tested in this study, phenylpropyl 
paromomcyin ether 3, 4’,6’-O-phenylpropylidene paromomycin acetal 5 are the 
most selective drugs as detailed in Table 4. Even though 4’-O-4-amino-α-D-
glucopyranosyl paromomycin 27 has comparable activity as parental 
paromomycin, its selectivity has been greatly compromised as evident in the 
small values of Mit13/Sms, A1555G/Sms, Cyt14/Sms (Table 4).  
The crystal structures of 4’-glycosyl paromomycin derivatives interacting with 
bacterial A site is not known yet. The lack of X-ray structures of the interaction of 
paromomycin with the mitochondrial A site limits the development of 
paromomycin derivatives with small binding affinity to the mitochondrial ribosome. 
Ultimately, an ideal AGA candidate should display a strong inhibiting activity 
towards the wild type bacterial ribosome translation while leaving the 
mitochondrial ribosome undisturbed. To that end, crystallographic and modeling 
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studies would be of a crucial need to make further advancements in the field. 
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PART II: UTILIZATION OF ELECTROSPRAY IONIZATION MASS 
SPECTROMETRY TO EVALUATE REACTIVITY OF GLYCOSYL PHOSPHATE 
 
CHAPTER 3 
INTRODUCTION 
3.1 One-Pot Oligosaccharide Synthesis 
  3.1.1 Challenges of Oligosaccharide Synthesis 
Oligosaccharides are involved in many biological processes, ranging from 
inflammation to immune response to viral infections.48-50 They are frequently 
found ligated to cell membrane proteins and control the information flow between 
different cells by triggering cell-cell recognition.51,52 If the automated synthesis of 
oligonucleotides and peptides is routine, efficient automated synthesis of 
complex oligosaccharides is still in expansion in the carbohydrate field. The 
difficulty in synthesizing oligosaccharides partly lies in the lack of general and 
selective glycosylation methods. As a result, the chemical synthesis of 
oligosaccharides frequently appears as a difficult and labor-intensive task with 
respect to the control of the stereoselectivity of the glycosidic bond formation as 
well as the multiple protection and deprotection manipulation steps.53 
 
   3.1.2 Introduction to One-Pot Oligosaccharide Synthesis 
Different approaches to oligosaccharide synthesis have been developed, 
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for instance solid-phase based synthesis, enzyme assisted synthesis and one-
pot sequential synthesis.54 The traditional solid-phase based synthesis requires 
complicated on-resin group protection and deprotection. On the other hand, the 
enzymatic synthesis could be used as an alternative, but the low availability and 
the high cost of the catalysts and substrates limit the usage of this technique.53 
Therefore, the one-pot sequential glycosylation is an advantageous method for 
oligosaccharide synthesis. The efficiency of this approach is based on the tuning 
of glycoside donors by varying protecting groups and the nature of the leaving 
group. The most reactive donor is placed at the non-reducing end while the least 
reactive one is placed at the reducing end. The one-pot synthesis therefore can 
be achieved by sequentially adding less active donors into the reaction system as 
shown in Scheme 5.49,50,54 
 
O
X
O
X
HO O
X
HO OHO OR
O O O O O OR
n
most reactive donor
less reactive least reactive reducing end !
   Scheme 5: Strategy for one-pot synthesis of linear oligosaccharidesa 
a) X represents the leaving group50 
 
3.1.3 Reactivity-Based One-Pot Synthesis of Oligosaccharides 
One pot synthesis allows to carry multiple sequential glycosylations to be 
conducted without the need for purification after each step. However, this method 
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is limited by the lack of precise reactivity values of building blocks49. In 1999, 
Wong et. al50 reported a general procedure to quantitatively measure the relative 
reactivity values (RRVs) of glycosyl donors using HPLC. In his study, Wong et al. 
used a direct competition assay as shown in Scheme 6.50 Two different glycosyl 
donors A1 and A2 were used in large excess in presence of a limited amount of 
electrophile (E+), to give the activated glycosyl intermediates B1 and B2. 
Secondly, B1 and B2 collapse into the transient oxocarbenium ions C1 and C2, 
which are finally trapped by the acceptors to form the desired products. The 
formation of the glycosyl oxocarbenium ion is assumed to be the rate-determining 
step of the reaction. As a result, a pseudo-first order reaction was observed. The 
RRVs were obtained from the relative ratio of the observed rate constants (kobs), 
which were calculated by monitoring the disappearance of glycosyl donors A1 
and A2 by HPLC (Equation 1). [At] stands for donor concentration at time t; [A0] 
stands for donor concentration at the beginning.50 
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Scheme 6: Competition experiment49 !!
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                                         RRV = kobs,1kobs,2
=
ln([A1,t ] / [A1,0 ])
ln([A2,t ] / [A2,0 ])
                          Equation 1   
 
  A library of the RRVs of fifty common glycosyl donors has been 
determined according to this protocol. In order to prove the applicability of this 
database, Wong et. al did a series of oligosaccharide synthesis based on the 
RRVs of glycosyl donors. The building blocks were added sequentially in order of 
decreasing RRVs50. During the years followed, Wong’s group was able to 
synthesize many oligosaccharides based on this RRV library.52,55-57  
 
3.2 Methods Using Electrospray Ionization Mass Spectrometry (ESI-MS) to 
Determine the relative stability of glycosides 
  3.2.1 Cone Voltage Fragmentation 
Electrospray ionization (ESI) uses electrical energy to transfer ions from 
solution into gaseous phase, and then ions are processed by the analyser.58 
When the sampling cone voltage is set at a low potential, for example 40V, the 
molecular ion reaches the mass analyzer intact. However, at higher voltage, an 
in-source collision-induced dissociation (CID) will take place. The sprayed 
charged species will accelerate between the sampling cone and the skimmer 
(Figure 7). During this process, the ions collide with the residual gas molecules. 
As a result, the kinetic energy is converted into internal energy to break the 
! 35!
!
bonds in the molecular ions.59 The kinetic energy got from the increased cone 
voltage is not that significant. The cone voltage fragmentation is only enough to 
break weak bonds within molecules ions. In this project, the fragmentation of 
glycosyl phosphate donors in regular ESI-MS were studied since the phosphate 
group is a good leaving group.  
     !
Figure 7. Schematic illustration of in-source fragmentation 
The purpose of this study is to establish a fast and accurate method to 
access the reactivity of glycosyl phosphate donors as a function of 
stereochemistry and protecting groups with the use of regular ESI-MS, 
considering that most organic laboratories have easy access to regular ESI-MS. 
An initial attempt to use ESI-MS cone fragmentation as a useful means to access 
the influence of protecting groups on the stability of the sialyl oxocarbenium ions, 
had been made by the Crich group.60 From the values of onset cone voltage as 
shown in Figure 8, it was concluded that the oxazolidinone and the carbonate 
protecting groups are strongly electron-withdrawing, and thus prevent the positive 
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charge to build up at the anomeric center. Therefore, higher cone voltages are 
required to fragment compounds 31-32 rather than compounds 28-30.60 
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Figure 8: Cone voltage fragmentation of sialyl phosphates60 !
  3.2.2 Collision Induced Dissociation Mass Spectrometry (CID-MS)  
CID-MS uses inert gas molecules to collide with accelerated molecular 
ions. Unlike the cone voltage fragmentation, CID-MS relies on a collision cell 
positioned between two mass analyzers to provide high potential to accelerate 
and then collide the ions (Figure 9). Compared to cone voltage fragmentation, the 
in-cell collision can provide more kinetic energy available to convert to internal 
energy. Therefore, the CID-MS can break stronger bonds than the cone voltage 
fragmentation. CID process is a sequence of two steps. The first step of this s 
(10-14 s to 10-16 s), and involves a collision between the molecular ions and an 
inert gas. During this step, part of the kinetic energy of the ions is transformed 
into internal energy, bringing the ions into an excited state. The activated ions 
then undergo an unimolecular decomposition in the subsequent step.61 With the 
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use of CID, Sandler et. al accessed the stability of glycosyl oxocarbenium ions 
and found that the pyranosides with trans configuration between the diacetyloxy 
groups at C1 and C2 is more active.62 They attributed it to the involvement of 
neighboring group participation.62 
!
Figure 9. Schematic illustration of CID mass spectrometer 
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CHAPTER 4 
UTILIZATION OF CONE VOLTAGE FRAGMENTATION AND CID TO ACCESS 
REACTIVITY OF GLYCOSYL PHOSPHATES 
4.1 Cone Voltage Fragmentation 
  4.1.1 Method for Quantitative Measurement 
In ESI-MS, the ion signal is proportional to the analyte concentration. 
Theoretically, the ion signal is linear from a concentration of the analyte ranging 
from pmol/L to µmol/L. Nevertheless, to make an accurate quantitative analysis, 
an internal standard is necessary to minimize the variations of sample 
preparation and sensitivity of mass spectrometer63. The aim of this study is to 
quantitatively determine the relative reactivity values of several glycosyl 
phosphate donors. With the use of NIS/TfOH activating system, a series of 
glycosyl phosphates were synthesized from their corresponding thioglycosides 60 
(see experimental part). The internal standard used here is the (2,3,4,6-tetra-O-
(p-methylbenzyl)-α-D-glucosyl) dibutylphosphate 33. Compared to glycosyl 
phosphate donors 34 and 35, the internal standard 33 has an extra mass of 56 
amu. Therefore, it is easy to differentiate from a mixture of the internal standard 
and the interested glycosyl phosphate donor, the peak of the internal standard 
phosphate based on the mass spectrum obtained. 
All the samples were prepared using the same amount of internal standard 
and of the interested glycosyl phosphate and were dissolved in a sodium acetate 
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methanolic solution ([NaOAc] = 0.18 mM). At the standard cone voltage of 40 V, 
both molecular ions hit the mass detector without losing phosphate groups 
(Figure 8A). As the cone voltage was increased gradually, both glycosyl 
phosphates began to fragment more as shown in Figure 8B. The fragment ions 
observed either resulted from the loss of dibutyl phosphoric acid from the 
parental molecular ion or from the loss of both dibutyl phosphoric acid and a the 
benzyl group from parental molecular ion60.  
The relative abundance of the fragmentation ion with respect to the 
parental molecular ion in the spectrum is a good reflection of the stability of 
glycosyl phosphates. The in-source fragmentation study of glycosyl phosphates 
was carried by increasing the cone voltage gradually from 40V until 2% 
fragmentation of the internal standard was observed. The relative stability value 
(RSV) was calculated as following: RSV=RM/RS, where RM is the relative 
abundance of fragmentation ion with respect to the corresponding parental 
interested glycosyl phosphate ion, and RS is the relative abundance of 
fragmentation ion with respect to the corresponding parental internal standard ion. 
An example of the mass spectra obtained from the fragmentation of glycosyl 
phosphates is shown in Figure 10; the fragmentation spectrum represented here 
is from (2,3,4,6-tetra-O-benzyl-α-D-mannosyl) dibutylphosphate. In Figure 8B, P1 
is the internal standard parental ion; P2 is (2,3,4,6-tetra-O-benzyl-α-D-mannosyl) 
dibutylphosphate parental ion; D1 is daughter ion of internal standard and  D2 is 
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daughter ion of (2,3,4,6-Tetra-O-benzyl-α-D-mannosyl) dibutylphosphate.  
 
!
Figure 10: Mass Spectrum of (2,3,4,6-Tetra-O-benzyl-α-D-mannosyl) dibutyl 
phosphate under different cone voltages. 
 
  4.1.2 Results and Discussion 
   A series of α, β anomers of mannosyl phosphates and glucosyl 
phosphates have been synthesized and tested quantitatively to determine their 
stability as shown in Table 5. Mannosyl phosphates and glucosyl phosphates 
were either fully protected with benzyl protecting groups or selectively protected 
with the 4,6-O-benzylidene acetal group. Based on the formula of RSV 
! 41!
!
calculation, it is obvious that as the RSV decreases, the stability of the glycosyl 
phosphate increases. During different fragmentation experiments, the cone 
voltage for internal standard achieving 2% fragmentation varies in 150 V-155 V 
region. This variation demonstrated the importance of using internal standard to 
ensure the accuracy and the reproducibility of these quantitative experiments. 
Comp
ound Sample structure CV
a Rs average RM average RSV average 
36α 
 
151 2.30±0.11 105.24±1.51 45.84±1.91 
37β 
 
150 2.43±0.01 84.47±0.33 34.76±0.11 
35β 
 
154 2.30±0.26 28.97±1.05 12.75±1.49 
34α 
 
155 2.34±0.11 23.56±0.66 10.08±0.42 
37α 
 
150 2.27±0.05 18.64±0.58 8.22±0.11 
36β 
 
152 2.27±0.12 8.16±0.32 3.59±0.08 
34β 
 
155 2.30±0.37 7.54±0.27 3.34±0.38 
35α 
 
155 2.40±0.10 7.54±0.19 3.14±0.12 
Table 6. Relative stability values from cone voltage fragmentationb 
a) CV stands for the cone voltage when internal standard glycosyl phosphate 
reaches approximately 2% fragmentation. 
b) Each fragmentation experiment was duplicated for three times. 
! 42!
!
 
The α anomers of glucosyl phosphates are more stable than their 
corresponding β anomers regardless of the protecting group used as show 
compounds 35α and 37α. In contrast, the α anomers of mannosyl phosphates 
are less stable than their corresponding β anomers irrespective of the protecting 
group used as show compounds 34α and 36α. Generally, it is accepted that α 
glycosyl phosphates are more stable than their β counterparts because of the 
anomeric effect. While studies from glucosyl phosphates support this assumption, 
the results from mannosyl phosphate studies contradict it. One possible 
explanation advances that when the dibutyl phosphate group at C1 is syn to the 
proton at C2 (compounds 34α, 35β, 36α, 37β), the observed fragmentation 
undergoes a one-step pericyclic syn-elimination (McLafferty rearrangement) 
(Scheme 7, path a) rather than going through the oxocarbenium ion formation as 
shown in pathway b (Scheme 7, path b)60.  Scheme 7 uses mannosyl phosphate 
donor 36α as an example to illustrate the two alternative pathways that take 
place during the fragmention of all the glycosyl phosphates studied here. 
Because the glycosyl oxocarbenium ion builds up a significant positive charge on 
the anomeric carbon, path b needs higher threshold energy to reach the transient 
oxocarbenium ion specie rather than path a. While path a is suitable for 
compounds 34α, 35β, 36α, 37β because of the favorable syn orientation of the 
dibutyl phosphate group at C1 with respect to the hydrogen atom at C2, such a 
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mechanism is not a possible for compounds 34β, 35α, 36β, 37α because of the 
anti periplanar orientation of the C1-O1 and C2-H2 bonds. As a result, 
compounds 34β, 35α, 36β, 37α have to go through the unfavorable path b. 
The McLafferty rearrangement is a common reaction observed during mass 
spectrometric fragmentation. In solution, the glycosylation proceeds through the 
formation of an oxocarbenium ion intermediate as outlined in path b (Scheme 7). 
Therefore, the RSVs of glycosyl phosphates carrying the dibutyl phosphate group 
at C1 trans to the hydrogen atom at C2 can be correlated to the reactivity of the 
glycosyl phosphates observed in glycosylation reactions since the fragmentation 
of compounds 34β, 35β, 36α and 37α follow the common formation of the 
oxocarbenium ion intermediate. 
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Scheme 7 Fragmentation mechanism 
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However, during the study of the influence of different protecting groups 
on the stability of glycosyl phosphates, it was found that glycosyl phosphate 
donors protected with 4, 6-O-benzylidene acetal groups are less stable than their 
corresponding tetra benzylated glycosyl phosphate donors with the only 
exception of 34β and 36β, which are similar to each other. Thus, the 4,6-O-
benzylidene-2,3-O-benzyl-α-D-glucosyl phosphate donor 37α was much less 
stable than the (2,3,4,6-tetra-O-benzyl-α-D-glucosyl) dibutyl phosphate donor 
35α. Yet, the 4,6-O-benzylidene-2,3-O-benzyl-β-D-mannosyl dibutyl phosphate 
36β donor was found to have a similar stability than the (2,3,4,6-tetra-O-benzyl-
β-D-mannosyl) dibutyl phosphate donor 34β. The results are contradictory to 
those usually observed in solution media where, for example, it was found that 
4,6-O-benzylidene protected glucoside was hydrolyzed more slowly than the 
corresponding 4,6-di-O-benzyl glucoside.64,65 The explanation advanced for this 
solution phase observation was attributed to the benzylidene effect, which results 
from locking C5-C6 bond in its most deactivating trans-gauche (tg) conformation 
leading to a maximization of the electron-withdrawing ability of the C6-O6 
bond66,67.  Therefore, it seems that the RSV cannot be used as a support to 
determine the reactivity of glycosyl phosphate donors in glycosylation reaction.  
 
4.2 CID Fragmentation 
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  4.2.1 Survival Yield  
With the use of CID-MS, it is possible to measure the stability of glycosyl 
phosphate donors without worrying about side reactions as parental molecular 
ions fragment in the collision cell in the gaseous state. In this study, the CID 
fragmentation experiment was carried on a Bruker amaZon ETD ion trap mass 
spectrometer. These experiments were conducted in collaboration with Dr. Mary 
Rodger’s group. The parental ions were fragmented with rf excitation energy 
(radio frequency energy) increasing from zero voltage until all the parental ions 
are fragmented. The survival yield of parental ion was calculated at each rf 
excitation energy applied. Hence, the survival yield curve obtained for each 
glycosyl phosphate donor is represented in Figure 11. The rf excitation energy 
used to achieve 50% fragmentation of the parental ion is used to access the 
stability of the glycosyl phosphate. The rf excitation energy applied at 50% 
fragmentation was named as SY50. As SY50 increases, the glycosyl phosphate is 
more stable. 
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Figure 11 Survival-yield curves of energy-resolved CID of eight glycosyl 
phosphates. Data were obtained on a Bruker amaZon ETD quadrupole ion 
trap mass spectrometer. Four parameter nonlinear dynamic fits to the 
survival-yield curves were generated to determine the rf excitation energies 
at which 50% of the precursor ions dissociate to evaluate the relative 
stabilities of the glycosyl phosphates. A) comparison of six glycosyl 
phosphates B) comparison of α,β anomers of 4,6-O-benzylidene-2,3-O-
benzyl-D-mannosyl phosphate. 
 
  4.2.2 Results and Discussion 
From the comparison of SY50 values of each glycosyl phosphate tested 
(Table 7), the CID fragmentation experiment gave similar result as it from the 
cone voltage fragmentation experiment. In other words, the α anomers of 
glucosyl phosphate are more stable than their corresponding β anomers 
regardless the protecting group used as show compounds 35α and 37α. Similarly, 
the α anomers of mannosyl phosphate are less stable than their corresponding β 
anomers irrespective with the protecting groups used as show compounds 34α 
and 36α. Glycosyl phosphate donors protected with 4, 6-O-benzylidene acetal 
groups are also less stable than their corresponding tetra benzylated glycosyl 
! 47!
!
phosphate donors with the only exception of α-glucosyl phosphate. It is likely that 
these glycosyl phosphates undergo the same mechanism pathway during the 
fragmentation step in either CID-MS or cone voltage fragmentation experiments. 
Comp
ound Sample structure 
RSV 
average SY50/V 
36α 
 
45.84±1.91 0.470±0.003 
37β 
 
34.76±0.11 0.471±0.003 
35β 
 
12.75±1.49 0.677±0.003 
34α 
 
10.08±0.42 0.655±0.040 
37α 
 
8.22±0.11 0.795±0.003 
36β 
 
3.59±0.08 0.780±0.004 
34β 
 
3.34±0.38 0.889±0.140 
35α 
 
3.14±0.12 0.737±0.003 
Table 7. Comparison of RSV from cone voltage fragmentation and SY50 
from CID-MS fragmentation 
 
4.3 Conclusion 
Based on the results obtained from both, cone voltage and CID 
fragmentation experiments, it is likely that glycosyl phosphates with the C1-
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dibutyl phosphate bond syn to the C2-H bond as for compounds 34α, 35β, 36α 
and 37β, dissociate through a McLafferty rearrangement. On the other hand, 
glycosyl phosphates with the C1-dibutyl phosphate bond anti to C2-H bond as for 
compounds 34β, 35α, 36β and 37α dissociate through an oxocarbenium ion, a 
common intermediate specie of the glycosylation reaction. However, based on 
the cone voltage fragmentation experiment, the 4,6-O-benzylidene protected 
glucosyl fragments more readily than the corresponding 4,6-di-O-benzyl glucosyl 
phosphate, which is contradictory to the well-known benzylidene effect. Therefore, 
the RSVs of compounds 34β, 35α, 36β and 37α cannot be used to determine the 
relative reactivity of the glycosyl phosphate donor. The different behavior of these 
glycosyl phosphate donors observed during ESI-MS fragmentation experiments, 
and not during the glycosylation reactions, is probably due to the fact that in ESI-
MS, the glycosyl phosphate donors are in a gaseous phase and exist as sodiated, 
unsolvated ions. Evidently, either sodiation or the lack of solution changes the 
order of oxocarbenium ion stability from that seen in solution. 
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CHAPTER 5 
EXPERIMENTAL SECTION 
General.  Glycosyl acceptor 1110 was prepared by the literature method.  All 
reactions were conducted under an inert atmosphere of nitrogen or argon.  ESI 
high resolution mass spectrometra were recorded with an electrospray source 
coupled to a time-of-flight mass analyzer. Optical rotation values were measured 
on an Autopol III automatic polarimeter. NMR data were acquired on either a 
Varian 500 MHz NMR machine or varian 600 MHz NMR machine for 1H and 13C 
spectra. 
A. General Procedure for Glycosylation under DPSO/TTBP/Tf2O Conditions.  
Dichloromethane solution of glycosyl donor  (0.47 mmol, 1.3 eq), DPSO (0.55 
mmol, 1.5 eq), TTBP (1.05 mmol, 2.9 eq) and activated 3 Å molecular sieves in 
dichloromethane (3 mL) was stirred at room temperature for 3 h before it was 
cooled to -72 °C temperature. Tf2O (0.55 mmol, 1.5 eq) was added slowly to the 
solution. After 1 h at the same temperature a solution of acceptor 11 (0.36 mmol, 
1 eq) in dichloromethane (1.5 mL) was added dropwise to the reaction mixture. 
The resulting solution was stirred at the same temperature for 2 h before the 
reaction was quenched by the addition of a saturated solution of NaHCO3.  The 
reaction mixture was diluted with EtOAc and the organic phase was washed with 
a saturated solution of NaHCO3 three times. The organic layer was dried over 
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Na2SO4, concentrated and purified by column chromatography over silica gel. 
B. General Procedure for the Reduction of Azides to Amines under 
Staudinger Reaction Conditions10.  The substrate (0.06 mmol, 1 eq) in THF (5 
mL) was treated at room temperature with 0.1M aqueous NaOH (0.3 mL, 0.03 
mmol, 5 eq) and 1M trimethylphosphine  in THF (0.6 mmol, 10 eq). The reaction 
mixture was stirred for 2 h at 50 °C, then cooled to room temperature. Before it 
was neutralized with 1 M AcOH solution to pH 7 before concentration.  The 
resulting slurry was subjected to silica gel chromatography, eluting first with 
MeOH (100 mL), followed by 0.5% aqueous NH4OH in MeOH (150 mL) to give 
the product. 
C. General Procedure for the Hydrogenolysis Reaction.  The substrate  was 
dissolved in a mixture of methanol (1 mL), deionized water H2O (2 mL), and 
glacial AcOH (0.1 mL).  A catalytic amount of Pd(OH)2 on carbon (20 wt. %) was 
added, and the reaction was stirred  at room temperature under 1 atm of 
hydrogen (balloon) overnight.  After completion, the reaction mixture was filtered 
over Celite® and the resulting filtrate was neutralized by the addition of 
Amberlite-IRA400 to pH 7 and filtered. The filtrate was concentrated to dryness 
and dissolved in 0.002 M aqueous AcOH solution (pH 4, 2 mL) before it was 
charged to a Sephadex column (CM Sephadex C-25).  The Sephadex column 
was flushed sequentially with dionized water H2O (50 mL), 0.5% aqueous 
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NH4OH (20 mL), and 1.5% NH4OH (40 mL). The fractions containing the 
hydrogenolysis product were combined and evaporated to give a sticky white 
solid, which was dissolved in 0.02 mM acetic acid  (pH 5, 1 mL).  The resulting 
solution was frozen by immersion in a dry ice acetone bath, and then the water 
was removed by lipholization to give the product as an acetate salt. 
 
 
1,3,2" ,2" " " ,6" "-Pentaazido-6,3" ,6" ,2" " ,5" " ,3" " " ,4" " "-hepta-O-benzyl-1,3,2" ,2" " " ,6" " "-
pentadeamino paromomycin (8).  A solution of potassium carbonate (24.2 g, 
176 mmol) in 1:1 MeOH:H2O (200 mL) was cooled on ice before paramomycin 
monosulfate (12.7 g, 20.7 mmol) was added slowly.  Then Stick’s reagent (26 g, 
124 mmol) was added portion-wise followed by a catalytic amount of copper 
sulfate. The reaction mixture was stirred at room temperature overnight during 
the course of which the color changed from blue to brown.  After completion, the 
reaction mixture was filtered and the resulting filtrate concentrated under vacuum 
at room temperature.  The remaining aqueous mixture was cooled on ice and 
acidifed  with 6 N hydrochloric acid to pH 3 and extracted with ethyl acetate three 
times.  The extracts were concentrated under vacuum to afford the title product 
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9.69 g (63%) in the form of a  light yellow solid with spectral data identical to the 
literature values.8 
4"-O-(4" " " " ,6" " " "-O-Benzylidene-2" " " " ,3" " " "-O-benzyl-α-D-mannopyranosyl)-
1,3,2" ,2" " " ,6" "-pentaazido-6,3" ,6" ,2" " ,5" " ,3" " " ,4" " "-hepta-O-benzyl-1,3,2" ,2" " " ,6" " "-
pentadeamino paromomycin (16α) and 4"-O-(4" " " " ,6" " " "-O-Benzylidene- 
2" " " " ,3" " " "-O-benzyl-β-D-mannopyranosyl)-1,3,2" ,2" " " ,6" "-pentaazido-
6,3" ,6" ,2" " ,5" " ,3" " " ,4" " "-hepta-O-benzyl-1,3,2" ,2" " " ,6" " "-
pentadeaminoparomomycin (16β).  Compounds 16α (76 mg), 16β (272 mg) 
were prepared from 11 (520 mg) by the general glycosylation procedure A.  The 
glycosylation was conducted at -60 °C for 2 h and then gradually increased to 
room temperature before quenching by saturated aqueous NaHCO3. The pure 
anomers were isolated in the form of white gums by gradient chromatography 
over silica gel (toluene:EtOAc 98:2 to 94:6) followed by preparative reverse 
phase-HPLC  (Varian dynamax 250*21.4 mm C18, acetonitrile:H2O 50:50 to 
100:0, 21.5 ml/min) in a α:β ratio of 1: 3.6 with a total yield of 51%.  
16α: [α]RTD -27.3 (c 0.21, CHCl3); 1H NMR (600 MHz, CDCl3) δ 7.50-7.00 (m, 50H, 
aromatic), 6.15 (d, J = 3.7 Hz, 1 H: H1'), 5.63 (d, J = 5.9 Hz, 1 H: H1''), 5.61 (s, 1 
H: PhCH), 5.23 (s, 1H: H1''''), 4.30-4.94 (m, 16 H: PhCH2), 4.86 (s, 1 H: H1'''), 
4.21-4.27 (m, 4 H: H4'', H4'''', H3'', PhCH2 ), 4.08-4.11 (m, 2 H: H6'''', PhCH2), 
4.05-4.10 (d, J = 9.9 Hz, 1 H: H5'), 3.97 (t, J = 9.2 Hz, 1 H: H3'), 3.90-3.94 (m, 3 
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H: H2'', H3'''', H5), 3.84-3.87 (m, 1 H: H5''''), 3.78 (t, J = 9.9 Hz, 1 H: H6''''), 3.74-
3.80 (m, 6 H: H5'', H6', H6', H2'''', H5''', H3'''), 3.66-3.70 (m, 2 H: H4', H4), 3.62 
(dd, J = 8.4 Hz, 12.9 Hz, 1 H: H6'''), 3.55 (dd, J = 3.3 Hz, 10.3 Hz, 1 H: H5''), 
3.39-3.50 (m, 2 H: H3, H1), 3.33 (s, 1 H: H2'''), 3.22 (t, J = 9.5 Hz, 1 H: H6), 3.11 
(s, 1 H: H4'''), 2.93 (dd, J = 3.7 Hz, 10.3 Hz, 1 H: H2'), 2.90 (d, J = 4.0 Hz, 12.8 
Hz, 1 H: H6'''), 2.20-2.24 (dt, J = 4.8 Hz, 13.2 Hz, 1 H: H2eq), 1.34 (m, 1 H: H2ax). 
13C NMR (125 MHz, CDCl3) δ 106.24 (C1''), 101.40 (PhCH), 101.29 (C1''''), 98.64 
(C1'''), 95.84 (C1'), 84.14 (C6), 82.28(C5), 82.05 (C4''), 81.96 (C2''), 79.94 (C3'), 
78.99 (C4''''), 77.96 (C2''''),77.76 (C4'), 76.27 (C3''''), 75.51 (C3''), 75.08 (C4), 
74.31 (C5'''), 72.89 (C3'''), 71.48 (C4'''), 70.61 (C5'), 70.16 (C5''), 69.25 (C6'), 
68.68 (C6''''), 65.32 (C5''''), 62.86 (C2'), 60.45 (C1), 60.27 (C3), 57.29 (C2'''), 
51.07 (C6'''), 32.12 (C2); PhCH2 (9C: 74.88, 74.82, 74.11, 73.93, 73.36, 73.25, 
73.16, 72.40, 71.73). HRESIMS calcd for C99H103N15O19Na [M+Na]+  1828.7452; 
found, 1828.7511. 
16β: [α]RTD +63.0 (c 0.33, CHCl3); 1H NMR (600 MHz, CDCl3) δ 7.70-7.00 (m, 
50H, aromatic), 6.20 (d, J = 4.0 Hz, 1 H: H1'), 5.70 (d, J = 5.9 Hz, 1 H: H1''), 5.54 
(s, 1 H: PhCH), 4.39-5.19 (m, 16 H: PhCH2), 4.95 (s, 1 H: H1'''), 4.45 (m, 1H: 
H1''''), 4.32-4.35 (m, 2 H: H4'', PhCH2 ), 4.27-4.29 (d, J = 12.1 Hz, PhCH2), 4.26 
(br s, 1 H, H3''), 4.17-4.20 (m, J = 9.9 Hz, 1 H: H5'), 4.03 - 4.14 (m, 3 H: H4'''', 
H6'''', H3'), 3.94-4.03 (m, 3 H: H4', H2'', H5), 3.71 - 3.81 (m, 6 H: H5'''', H2'''', H5'', 
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H3''', H4, H5''' ), 3.67-3.70 (d, J = 11.3 Hz, 1H: H6'), 3.58-3.63 (m, 2 H: H5'', H6'''), 
3.50-3.55 (dt, J = 3.8 Hz, 10.3 Hz, 1 H: H3), 3.42-3.49 (m, 2 H: H6'''', H1), 3.39 
(dd, J = 0.7 Hz, 9.9 Hz, 1 H: H3''''), 3.36 (br s, 1 H: H2'''), 3.29-3.34 (t, J = 9.2 Hz, 
1 H: H6), 3.24-3.28 (dd, J = 4.0 Hz, 10.3 Hz, 1 H: H2'), 3.15 (br s, 1 H: H4'''), 
3.07-3.11 (dt, J = 4.8 Hz, 9.6 Hz, 1 H: H5''''), 2.92-2.95 (dd, J = 4.4 Hz, 13.2 Hz, 1 
H: H6'''), 2.26 (dt, J = 4.5 Hz, 8.6 Hz, 1 H: H2eq), 1.41 (m, 1 H: H2ax). 13C NMR 
(151 MHz, CDCl3) δ 106.17 (C1''), 101.71 (C1''''), 101.33 (PhCH), 98.71 (C1'''), 
95.81 (C1'), 84.14 (C6), 82.35 (C4''), 82.10 (C5), 81.86 (C2''), 78.53 (C3'), 78.15 
(C4''''), 77.92 (C3''''),77.49 (C4'), 76.70 (C2''''), 75.63 (C3'), 74.99 (C4), 73.74 
(C5'''), 73.48 (C3'''), 71.46 (C4'''), 70.66 (C5'), 70.03 (C5''), 68.61 (C6''''), 68.49 
(6'), 67.38 (C5''''), 62.60 (C2'), 60.39 (C1), 60.31 (C3), 57.34 (C2'''), 51.00 (C6'''), 
32.72 (C2); PhCH2 (9C: 75.10, 75.05, 74.98, 74.21, 73.30, 72.94, 72.42, 72.25, 
71.76). HRESIMS calcd for C99H103N15O19Na [M+Na]+  1828.7452; found, 
1828.7444. 
4"-O-(2" " " " ,3" " " " ,4" " " " ,6" " " "-Tetra-O-benzyl-α-D-glucopyranosyl)-1,3,2" , 2" " " ,6" "-
pentaazido-6,3" ,6" ,2" " ,5" " ,3" " " ,4" " "-hepta-O-benzyl-1,3,2" ,2" " " ,6" " "-
pentadeamino paromomycin (17α) and 4"-O-(2" " " " ,3" " " " ,4" " " " ,6" " " "-Tetra -O-
benzyl-β-D-glucopyranosyl)-1,3,2" , 2" " " ,6" "-pentaazido-6,3" ,6" ,2" " ,5" " ,3" " " , 4" " "-
hepta-O-benzyl-1,3,2" ,2" " " ,6" " "-pentadeamino paromomycin (17β). 
Compounds 17α (221 mg), 17β (69 mg) were prepared from 11 (500 mg) by the 
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general glycosylation procedure A, which was conducted at -60 °C for 1 h and 
then at -50 °C for 1 h before quenching with saturated aqueous NaHCO3.  The 
pure anomers were isolated in the form of white gums by chromatography over 
silica gel using a gradient eluate toluene:EtOAc 98:2 to 95:5, followed by 
preparative HPLC over silica gel (Agilent dynamax 250*21.4 mm SI, Hexanes: 
EtOAc 90:10, 21.5 ml/min) in a α:β  ratio of 3.2: 1 and  a combined yield of 42%.  
17α: [α]RTD +71.7 (c 4.20, CHCl3); 1H NMR (600 MHz, CDCl3) δ 7.50-7.00 (m, 
55H, aromatic), 6.11 (d, J = 4.03 Hz, 1 H: H1'), 5.64 (d, J = 5.5 Hz, 1 H: H1''), 
5.44 (d, J = 2.94 Hz, 1 H: H1''''), 4.95 (m, 22 H: PhCH2), 4.56 (s, 1 H, H1'''), 4.30 
(s, 1 H: H4''), 4.29 (s, 1 H: H3''), 4.22 (d, J = 9.9 Hz, 1 H: H5'), 4.12 (t, J = 9.35 Hz, 
1 H: H3'), 4.00-3.90 (m, 5 H: H2'', H3'''', H6', H4', H5), 3.83 (d, J = 10.64, 1 H: 
H5''''), 3.81-3.75 (m, 4 H: H6', H5'', H5''', H3'''), 3.69 (t, J = 9.17 Hz, 1 H: H4), 
3.66-3.60 (m, 2 H: H6''', H4'''' ), 3.55 - 3.60 (m, 2 H: H5'', H6''''), 3.40 - 3.51 (m,  4 
H: H2'''', H6'''', H3, H1), 3.36 (s, 1 H: H2'''), 3.25 (t, J = 9.35 Hz, 1 H: H6), 3.16 (s, 
1 H: H4'''), 3.11 (dd, J = 3.9 Hz, 9.8 Hz, 1 H: H2'), 2.92 (dd, J = 4.2 Hz, 12.8 Hz, 1 
H: H6'''), 2.24 (dt, J = 4.5 Hz, 8.6 Hz, 1 H: H2eq), 1.31-1.41 (m, 1 H: H2ax). 13C 
NMR (151 MHz, CDCl3) δ 106.27 (C1''), 98.57 (C1'''), 97.47 (C1''''), 95.99 (C1'), 
83.95 (C6), 82.17 (C2''), 81.91 (C4''), 81.89 (C3''''), 81.86 (C5), 79.80 (C3'), 79.59 
(C2''''), 77.61 (C4''''), 75.53 (C3''), 75.44 (C4), 74.26 (C4'), 73.67 (C5'''), 71.49 
(C5'), 71.10 (C5''''), 70.88 (C3'''), 70.15 (C6'), 69.34 (C5''), 68.41(C6''''), 62.78 
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(C2'), 60.38 (C1), 59.90 (C3), 57.33 (C2'''), 51.03 (C6'''), 32.38 (C2); PhCH2 (11C: 
75.31, 75.00, 74.90, 73.39, 73.23, 73.14, 73.07, 72.91, 72.85, 72.40, 71.74). 
HRESIMS calcd for C106H111N15O19Na [M+Na]+ , 1920.8078; found, 1920.8175. 
17β: [α]RTD +60.3 (c 0.80, CHCl3); 1H NMR (600 MHz, CDCl3) δ 7.70-7.00 (m, 
55H, aromatic), 6.09 (d, J = 4.03 Hz, 1 H: H1'), 5.62 (d, J = 5.50 Hz, 1 H: H1''), 
5.13-4.22 (m, 22 H: PhCH2), 4.82 (s, 1 H: H1'''), 4.38 (m, 1H: H1''''), 4.24 (s, 1 H: 
H4''), 4.20 (s, 1 H, H3''), 4.13 (m, J = 9.9 Hz, 1 H: H5'), 3.97-4.12 (m, 2 H: H3', 
H4'), 3.81-3.96 (m, 3 H: H6', H2'', H5), 3.59-3.73 (m, 5 H: H6'''', H5'', H3''', H6', 
H5''' ), 3.65 (t, J = 11.2 Hz, 1H: H4), 3.61 (t, J = 9.35 Hz, 1 H: H4''''), 3.49-3.56 (m, 
4 H: H6''', H5'', H3'''', H6'''' ), 3.34-3.46 (m, 3 H: H3, H2'''', H1), 3.30 (m, 1 H: H5''''), 
3.34 (s, 1 H: H2'''), ) 3.22 (t, J = 9.35 Hz, 1 H: H6), 3.12 (m, 1 H: H2'), 3.10 (s, 1 H: 
H4'''), 2.86-2.92 (dd, J = 4.4 Hz, 13.2 Hz, 1 H: H6'''), 2.18 (dt, J = 4.5 Hz, 8.6 Hz, 
1 H: H2eq), 1.27-1.34 (m, 1 H: H2ax). 13C NMR (600 MHz, CDCl3) δ 105.99 (C1''), 
102.87 (C1'''), 98.66 (C1''''), 95.84 (C1'), 84.71 (C3''''), 84.05 (C6), 82.61 (C2''''), 
82.23 (C4''), 81.97 (C2''), 81.70 (C5), 77.99 (C4''''),77.50 (C3'), 77.21 (C4'), 75.59 
(C3'''), 75.17 (C5''''), 74.72 (C4), 74.09 (C5'''), 73.08 (C3'''), 71.71 (C5'), 69.86 
(C6''''), 69.00 (C5''), 67.96 (C6'), 62.62 (C2'), 60.34 (C1), 60.19 (C3), 57.30 (C2'''), 
50.89 (C6'''), 32.64 (C2); PhCH2 (11C: 75.55, 75.10, 75.01, 74.90, 74,83, 73.23, 
73.21, 72.90, 72.35, 71.41, 70.99).  HRESIMS calcd for C106H111N15O19Na 
[M+Na]+ , 1920.8078; found, 1920.8156. 
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4"-O-(2" " " " ,3" " " " ,4" " " " ,6" " " "-Tetra-O-benzyl-α-D-galactopyranosyl)-1,3,2" , 
2" " " ,6" "-pentaazido-6,3" ,6" ,2" " ,5" " ,3" " " ,4" " "-hepta-O-benzyl-1,3,2" ,2" " " ,6" " "-
pentadeamino paromomycin (18α) and 4"-O-(2" " " " ,3" " " " ,4" " " " ,6" " " "-Tetra-O-
benzyl-β-D-galactopyranosyl)-1,3,2" ,2" " " ,6" "-pentaazido-6,3" ,6" ,2" " ,5" " ,3" " " ,4" " "-
hepta-O-benzyl-1,3,2" ,2" " " ,6" " "-pentadeamino paromomycin (18β). 
Compounds 18α (358 mg), 18β (56 mg) were prepared from 11 (500 mg) by the 
general glycosylation procedure A, which was conducted at -72 °C for 2 h before 
quenching with saturated aqueous NaHCO3. The pure anomers were isolated as 
white gums by gradient chromatography over silica gel (toluene:EtOAc 98:2 to 
94:6).  The two anomers were obtained as white gums with  a α:β ratio of 6.4: 1 
with a total yield of 60%.  
18α: [α]RTD +82.97 (c 6.33, CHCl3); 1H NMR (600 MHz, CDCl3) δ 7.50-7.00 (m, 
55H, aromatic), 6.12 (d, J = 4.03 Hz, 1 H: H1'), 5.66 (d, J = 5.50 Hz, 1 H: H1''), 
5.54 (d, J = 3.67 Hz, 1 H: H1''''), 4.91-4.34 (m, 21 H: PhCH2), 4.88-4.91 (br s, 1 H, 
H1'''), 4.31-4.30 (m, 3 H: H4'', H3'', PhCH2), 4.22-4.27 (dd, J = 3.3 Hz, 9.9 Hz, 1 
H: H5'), 4.11 (t, J = 10.27 Hz, 1 H: H3'), 4.02-4.04 (dd, J = 3.45 Hz, 10.30 Hz, 1 H: 
H2'''' ), 4.01-3.98 (m, 2 H: H5'''', H2''), 3.96-3.98 (br s, 1 H: H4''''), 3.85-3.96 (m, 4 
H: H3'''', H5, H6', H4'), 3.76-3.84 (m, 4 H: H6', H5'', H3''', H5'''), 3.73 (t, J = 9.35 
Hz, 1 H: H4), 3.65 (dd, J = 8.44 Hz, 12.84Hz, 1 H: H6'''), 3.57-3.62 (dd, J = 
3.11Hz, 10.27 Hz, 1 H: H5''), 3.50-3.55 (m, 2 H: H6''''), ) 3.41-3.50 (m, 2 H: H3, 
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H1), 3.36-3.41 (br s, 1 H: H2'''), 3.27 (t, J = 9.35 Hz, 1 H: H6), 3.14-3.18 (s, 1 H: 
H4'''), 3.09 (dd, J = 3.67 Hz, 10.27 Hz, 1 H: H2'), 2.95 (dd, J = 4.2 Hz, 13.02 Hz, 
1 H: H6'''), 2.24 (dt, J = 4.5 Hz, 8.6 Hz, 1 H: H2eq), 1.33-1.39 (m, 1 H: H2ax). 13C 
NMR (151 MHz, CDCl3) δ 120-144 (55C: aromatic), 106.27 (C1''), 98.63 (C1'''), 
98.22 (C1''''), 95.91 (C1'), 84.01 (C6), 82.24 (C2''), 81.96 (C4''), 81.94 (C3''), 
79.94 (C3'), 78.87 (C5), 75.97 (C2''''),75.53 (C3''), 75.28 (C4), 75.09 (C4'), 75.07 
(C4''''), 74.28 (C5'''), 72.98 (C3'''), 71.57 (C4'''), 70.82 (C5'), 70.16 (C5''), 70.14 
(C5''''), 69.73 (C6'), 69.08 (C6''''), 62.92 (C2'), 60.42 (C1), 60.00 (C3), 57.38 
(C2'''), 51.05 (C6'''), 32.46 (C2); PhCH2 (11C: 74.94, 74.72, 73.80, 73.38, 73.30, 
73.28, 73.19, 72.93, 72.89, 72.43, 71.79). HRESIMS calcd for C106H111N15O19Na 
[M+Na]+ , 1920.8078; found, 1920.8009.  
18β: [α]RTD +42.37 (c 3.25, CHCl3); 1H NMR (600 MHz, CDCl3) δ 7.50-7.00 (m, 
55H, aromatic), 6.12 (d, J = 3.7 Hz, 1 H: H1'), 5.65 (d, J  = 5.9 Hz, 1 H: H1''), 
5.14-4.23 (m, 22 H: PhCH2), 4.81 (s, 1 H: H1'''), 4.38 (d, J = 7.0 Hz, 1H: H1''''), 
4.20-4.27 (m, 3 H: H4'', H5', H3''), 4.03-4.07 (t, J = 9.2 Hz, 1 H: H3'), 3.99-4.02 (t, 
J = 9.2 Hz, 1 H: H4'), 3.90 - 3.98 (m, 4 H: H6', H2'', H5, H5''''), 3.82 (dd, J = 9.9, 
7.7 Hz, 1 H: H2''''), 3.66 - 3.79 (m, 5 H: H4, H5'', H3''', H6', H5''' ), 3.52-3.58 (m, 3 
H: H6''', H5'', H6'''' ), 3.42-3.50 (m, 2 H: H3, H1), 3.40 (dd, J = 3.0 Hz, 9.9 Hz, 1 H: 
H3''''), 3.33-3.37 (m, 2 H: H4'''', H6''''), 3.32 (br s, 1 H: H2'''), 3.24-3.27 (t, J = 9.5 
Hz, 1 H: H6), 3.18-3.23 (dd, J = 4.8 Hz, 12.8 Hz, 1H: H2'), 3.10-3.15 (br s, 1H: 
! 59!
!
H4'''), 2.93 (dd, J = 4.8 Hz, 12.8 Hz, 1 H: H6'''), 2.24 (dt, J = 4.5 Hz, 8.6 Hz, 1 H: 
H2eq), 1.30-1.40 (m, 1 H: H2ax). 13C NMR (151 MHz, CDCl3) δ 120-144 (55C: 
aromatic), 106.04 (C1''), 103.08 (C1'''), 98.68 (C1''''), 95.78 (C1'), 84.06 (C6), 
82.29 (C5), 82.26 (C3''''), 82.00 (C4''), 81.76 (C2''), 79.95 (C2''''), 78.09 (C3'), 
76.65 (C4'), 75.63 (C3''), 74.75 (C4), 74.10 (C5'''), 73.81 (C5''''), 73.14 (C4''''), 
72.99 (C3'''), 71.07 (C5'), 69.92 (C5''), 68.13 (C6''''), 68.06 (C6'), 62.74 (C2'), 
60.20 (C1), 60.03 (C3), 57.34 (C2'''), 50.91 (C6'''), 32.65 (C2), PhCH2 (11C: 
75.35, 75.27, 75.01, 74.80, 73.37, 73.26, 73.24, 72.91, 72.69, 72.39, 71.76). 
HRESIMS calcd for C106H111N15O19Na [M+Na]+ , 1920.8078; found, 1920.8101. 
4"-O-(2" " " " ,3" " " " ,6" " " "-Tri-O-benzyl-4" " " "-azido-4" " " "-deoxy-α-D-glucopyranosyl)-
1,3,2" ,2" " " ,6" "-pentaazido-6,3" ,6" ,2" " ,5" " ,3" " " ,4" " "-hepta-O-benzyl-1,3,2" ,2" " " ,6" " "-
pentadeamino paromomycin (19α) and 4"-O-(2" " " " ,3" " " " ,6" " " "-Tri-O-benzyl-
4" " " "- azido-4" " " "-deoxy-β-D-glucopyranosyl)-1,3,2" ,2" " " ,6" "-pentaazido-6,3" ,6" , 
2" " ,5" " ,3" " " ,4" " "-hepta-O-benzyl-1,3,2" ,2" " " ,6" " "-pentadeamino paromomycin 
(19β). Compounds 19α (272 mg), 19β (61 mg) were prepared from 11 (500 mg) 
by the general glycosylation procedure A, conducted  at -60 °C for 1 h and then -
50 °C for 1 h before quenching by saturated aqueous NaHCO3. The two anomers 
were isolated as white gums by gradient chromatography over silica gel 
(toluene:EtOAc 98:2 to 94:6) followed by  to preparative reverse phase HPLC 
((Varian dynamax 250*21.4 mm C18, acetonitrile:H2O 70:30 to 100:0, 21.5 
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ml/min)) in a α:β ratio of  4.5: 1 with a total yield of 50%.  
19α: [α]RTD +93.21 (c 3.73, CHCl3); 1H NMR (600 MHz, CDCl3) δ 7.50-7.00 (m, 
50H, aromatic), 6.10 (d, J = 4.0 Hz, 1 H: H1'), 5.61 (d, J = 5.5 Hz, 1 H: H1''), 5.41 
(d, J = 3.7 Hz, 1 H: H1''''), 4.94-4.30 (m, 19 H: PhCH2), 4.85 (s, 1 H, H1'''), 4.24-
4.29 (m, 3 H: H4'', H3'', PhCH2), 4.14-4.20 (d, J = 9.9 Hz, 1 H: H5'), 4.07-4.13 (t, 
J = 9.2 Hz, 1 H: H3'), 3.94-3.96 (t, J = 5.1 Hz, 1 H: H2''), 3.90-3.93 (m, 3 H: H4', 
H5, H6'), 3.82 (t, J = 9.4 Hz, 1 H: H3'''' ), 3.74-3.78 (m, 3 H: H5'', H3''', H5'''), 3.73 
(t, J = 8.4 Hz, 1 H: H6'), 3.67 (t, J = 9.5 Hz, 1 H: H4), 3.59-3.63 (m, 3 H: H6''', 
H4'''', H5'''' ), 3.55 (dd, J = 3.3 Hz, 10.3 Hz, 1 H: H5''), 3.39-3.49 (M, 5 H: H3, H6'''', 
H2'''', H6'''', H1), 3.32-3.36 (br s, 1 H: H2'''), 3.24 (t, J = 9.4 Hz, 1 H: H6), 3.11-
3.15 (br s, 1 H: H4'''), 3.08 (dd, J = 10.1, 3.9 Hz, 1 H: H2'), 2.91 (dd, J = 13.0, 4.2 
Hz, 1 H: H6'''), 2.24 (dt, J = 4.5 Hz, 8.6 Hz, 1 H: H2eq), 1.30-1.39 (m, 1 H: H2ax). 
13C NMR (151 MHz, CDCl3) δ 120-144 (55C: aromatic), 106.30 (C1''), 98.57 
(C1'''), 97.26 (C1''''), 95.96 (C1'), 81.89 (C5), 79.76 (C3''''), 79.69 (C3'), 79.42 
(C2''''), 77.21 (C6), 76.99 (C2''), 76.78 (C4''), 75.53 (C3''), 75.36 (C4), 74.25 (C4'), 
72.39 (C3'''), 71.52 (C4'''), 70.84 (C5'), 70.19 (C4''''), 70.14 (C5''), 69.20 (C6'), 
68.51 (C6''''), 62.66 (C2'), 61.60 (C4''''), 60.38 (C1), 60.03 (C3), 57.32 (C2'''), 
51.04 (C6'''), 32.45 (C2); PhCH2 (10C: 75.44, 75.01, 74.61, 73.39, 73.21, 73.17, 
73.11, 72.93, 72.75, 71.75). HRESIMS calcd for C99H104N18O18Na [M+Na]+ , 
1855.7674; found, 1855.7692. 
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19β: [α]RTD +78.7 (c 1.87, CHCl3); 1H NMR (600 MHz, CDCl3) δ 7.50-7.00 (m, 
50H, aromatic), 6.12 (d, J = 4.0 Hz, 1 H: H1'), 5.63 (d, J = 5.9 Hz, 1 H: H1''), 
5.09-4.29 (m, 21 H: PhCH2), 4.80 (s, 1 H: H1'''), 4.32 (d, J = 7.7 Hz, 1H: H1''''), 
4.24-4.26 (m, 2 H: H4'', PhCH2), 4.20 (m, H3''), 4.18 (d, J = 9.5 Hz, J 1 H: H5'), 
4.01 (m, 2 H: H3', H4'), 3.88-3.96 (m, 3 H: H6', H2'', H5), 3.68-3.76 (m, 4 H: H5'', 
H3''', H5''', H6'), 3.65-3.67 (m, 2 H: H4, H6''''), 3.60 (t, J = 9.9 Hz, 1 H: H4''''), 
3.52-3.59 (m, 2 H: H6''', H5''), 3.48 (dd, J = 4.4 Hz, 11.0 Hz, 1 H: H6''''), 3.39-3.43 
(m, 2 H: H1, H3), 3.37 (t, J = 8.4 Hz, 1 H: H2''''), 3.31 (br s, 1 H: H2'''), 3.27 (t, J = 
9.2 Hz, 1 H: H3''''), 3.24 (t, J = 9.5 Hz, 1 H: H6), 3.13 (dd, J = 4.0 Hz, 9.9 Hz), 
3.11 (br s, 1 H: H4'''), 3.02 (ddd, J = 1.5 Hz, 4.0 Hz, 6.2 Hz, 1 H: H5''''), 2.91 (dd, 
J = 4.4 Hz, 12.8 Hz, 1 H: H6'''), 2.24 (dt, J = 4.5 Hz, 8.6 Hz, 1 H: H2eq), 1.29-1.36 
(m, 1 H: H2ax). 13C NMR (151 MHz, CDCl3) δ 120-144 (50C: aromatic), 106.04 
(C1''), 102.71 (C1'''), 98.66 (C1''''), 95.89 (C1'), 84.05 (C6), 82.77 (C3''''), 82.26 
(C2'', C2'''' ), 81.99 (C4''), 81.73 (C5), 77.79 (C3'), 77.02 (C4'), 76.77 (C3''), 74.82 
(C4), 74.11 (C5''''), 74.07 (C5'''), 72.91 (C3'''), 71.43 (C4'''), 70.90 (C5'), 69.89 
(C5''), 69.16 (C6''''), 67.88 (C6'), 62.64 (C2'), 62.08 (C4''''), 60.35 (C1), 60.19 (C3), 
57.31 (C2'''), 50.92 (C6'''), 32.64 (C2), PhCH2 (10C: 76.77, , 75.19, 75.03, 74.87, 
73.31, 73.24, 73.21, 72.91, 72.37, 71.73). HRESIMS calcd for C99H104N18O18Na 
[M+Na]+ , 1855.7674; found, 1855.7615. 
4"-O-(4" " " " ,6" " " "-O-Benzylidene-2" " " " ,3" " " "-O-benzyl-α-D-mannopyranosyl)-6, 
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3" ,6" ,2" " ,5" " ,3" " " ,4" " "-hepta-O-benzyl-1,3,2" ,2" " " ,6" " "-pentadeamino 
paromomycin (20α). Compound 20α (17 mg, 91%) was obtained in the form of 
a white gum from 16α (20 mg) by Staudinger reaction general procedure B after  
silica gel chromatography (NH4OH: MeOH 0: 100 to 1:99) . [α]RTD +10.2 (c 0.93, 
MeOH); HRESIMS calcd for C99H114N5O19[M+H]+ , 1676.8108; found, 1676.8175.  
This compound was taken forward to the next step without further 
characterization. 
4"-O-(4" " " " ,6" " " "-O-Benzylidene-2" " " " ,3" " " "-O-benzyl-β-D-mannopyranosyl)-6, 
3" ,6" ,2" " ,5" " ,3" " " ,4" " "-hepta-O-benzyl-1,3,2" ,2" " " ,6" " "-pentadeamino 
paromomycin (20β). Compound 20β (68 mg, 66%) was obtained in the form of 
a white gum under the Staudinger reaction general procedure B of 110 mg 16β 
(110 mg) after silica gel chromatography (NH4OH: MeOH 0: 100 to 1:99 ). [α]RTD -
5.5 (c 1.75, MeOH); HR ESI MS calcd for C99H114N5O19[M+H]+ , 1676.8108; 
found, 1676.8066.  This compound was taken forward to the next step without 
further characterization. 
4"-O-(2" " " " ,3" " " " ,4" " " " ,6" " " "-Tetra-O-benzyl-α-D-glucopyranosyl)-
6,3" ,6" ,2" " ,5" " ,3" " " ,4" " "-hepta-O-benzyl-1,3,2" ,2" " " ,6" " "-pentadeamino 
paromomycin (21α). Compound 21α (35 mg, 64%) was obtained as a white 
gum under the Staudinger reaction general procedure B of 17α (60 mg) after 
silica gel chromatography (NH4OH: MeOH 0: 100 to 1:99). [α]RTD +27.50 (c 2.00, 
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MeOH); HRESIMS calcd for C106H122N5O19 [M+H]+, 1768.8734; found, 1768.8747.  
This compound was taken forward to the next step without further 
characterization. 
4"-O-(2" " " " ,3" " " " ,4" " " " ,6" " " "-Tetra-O-benzyl-β-D-glucopyranosyl)-
6,3" ,6" ,2" " ,5" " ,3" " " ,4" " "-hepta-O-benzyl-1,3,2" ,2" " " ,6" " "-pentadeamino 
paromomycin (21β). Compound 21β (17 mg, 55%) was obtained as a white 
gum under the Staudinger reaction general procedure B of 17β (33 mg) after 
silica gel chromatography (NH4OH: MeOH 0: 100 to 1:99). [α]RTD -2.1 (c 0.52, 
MeOH); HRESIMS calcd for C106H122N5O19 [M+H]+, 1768.8734; found, 1768.8700.  
This compound was taken forward to the next step without further 
characterization. 
4"-O-(2" " " " ,3" " " " ,4" " " " ,6" " " "-Tetra-O-benzyl-α-D-galactopyranosyl)-
6,3" ,6" ,2" " ,5" " ,3" " " ,4" " "-hepta-O-benzyl-1,3,2" ,2" " " ,6" " "-pentadeamino 
paromomycin (21α). Compound 21α (83 mg, 81%) was obtained as a white 
gum under the Staudinger reaction general procedure C of 110 mg 17α (110 mg) 
after silica gel chromatography (NH4OH: MeOH 0: 100 to 1:99). [α]RTD +42.7 (c 
6.67, MeOH); HRESIMS calcd for C106H122N5O19 [M+H]+, 1768.8734; found, 
1768.8707.  This compound was taken forward to the next step without further 
characterization. 
4"-O-(2" " " " ,3" " " " ,4" " " " ,6" " " "-Tetra-O-benzyl-β-D-galactopyranosyl)-
6,3" ,6" ,2" " ,5" " ,3" " " ,4" " "-hepta-O-benzyl-1,3,2" ,2" " " ,6" " "-
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pentadeaminoparomomycin (22β). Compound 22β (24 mg, 78%) was obtained 
as a white gum under the Staudinger reaction general procedure B of 18β (33 
mg) after silica gel chromatography (NH4OH: MeOH 0: 100 to 1:99). [α]RTD -5.2 (c 
0.56, MeOH); HRESIMS calcd for C106H122N5O19 [M+H]+, 1768.8734; found, 
1768.8732.  This compound was taken forward to the next step without further 
characterization. 
4"-O-(2" " " " ,3" " " " ,6" " " "-Tri-O-benzyl-4" " " "-amino-4" " " "-deoxy-α-D-
glucopyranosyl)-6,3" ,6" ,2" " ,5" " ,3" " " ,4" " "-hepta-O-benzyl-1,3,2" ,2" " " ,6" " "-
pentadeamino paromomycin (23α). Compound 23α (23 mg, 64%) was 
obtained as a white gum under the Staudinger reaction general procedure B of 
40 mg 19α (40 mg) after silica gel chromatography (NH4OH: MeOH 0: 100 to 
1:99). [α]RTD +23.0 (c 0.80, MeOH); HRESIMS calcd for C99H117N6O18 [M+H]+, 
1677.8424; found, 1677.8425.  This compound was taken forward to the next 
step without further characterization. 
4"-O-(2" " " " ,3" " " " ,6" " " "-Tri-O-benzyl-4" " " "-amino-4" " " "-deoxy-β-D-
glucopyranosyl)-6,3" ,6" ,2" " ,5" " ,3" " " ,4" " "-hepta-O-benzyl-1,3,2" ,2" " " ,6" " "-
pentadeamino paromomycin (23β). Compound 23β (18 mg, 48%) was 
obtained as a white gum under the Staudinger reaction general procedure B of 
19β (28 mg) after silica gel chromatography (NH4OH: MeOH 0: 100 to 1:99). 
[α]RTD +5.9 (c 1.20, CHCl3); HRESIMS calcd for C99H117N6O18 [M+H]+, 1677.8424; 
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found, 1677.8474.  This compound was taken forward to the next step without 
further characterization. 
4’-O-α-D-Mannopyranosyl paramomycin(24α). Compound 24α (4 mg, 33%) 
was obtained in the form of a white solid by hydrogenolysis general producedure 
C of 20α (17 mg) after Sephadex chromatography. [α]RTD +55.0 (c 0.18, H2O); 1H 
NMR (600 MHz, CDCl3) δ 5.59 (d, J = 4.1 Hz, 1 H: H1'), 5.21 (br s, 1 H: H1''), 
5.12 (s, 1 H: H1'''), 5.09 (m, 1H: H1''''), 4.37 (t, J = 5.5 Hz, 1 H: H3''), 4.23 (s, 1 H: 
H2''), 4.15 (s, 1 H: H5'''), 4.06 (s, 1 H: H3'''), 4.04 (s, 1 H: H4''), 3.92 (t, J = 8.8 Hz, 
1 H: H3'), 3.88 (s, 1 H: H2''''), 3.63-3.79 (m, 7 H: H6'''', H5'', H5', H6', H5, H6', 
H4''', H4), 3.54-3.63 (m, 4 H: H3'''', H6'''', H5'', H4'), 3.43-3.52 (m, 3 H: H5'''', H4'''', 
H6), 3.41 (s, 1 H: H2'''), 3.17-3.28 (m, 3 H: H6''', H6''', H2'), 3.09-3.15 (m, 2 H: H1, 
H3), 2.17 (m, 1 H: H2eq), 1.50 (m, 1 H: H2ax). 13C NMR (151 MHz, CDCl3) δ 
109.98 (C1''), 101.49 (C1''''), 95.64 (C1'), 95.27 (C1'''), 84.63 (C5), 81.01 (C4''), 
79.02 (C4), 75.54 (C4'), 74.93 (C3''), 73.82 (C5''''), 73.27 (C6), 72.79 (C2''), 72.48 
(C5'), 70.19 (C3''''), 70.16 (C5'''), 69.98 (C2''''), 69.41 (C3'), 67.62 (C3'''), 67.20 
(C4'''), 66.36 (C4''''), 60.80 (C6''''), 60.03 (C6'), 59.94 (C5''), 53.84 (C2'), 50.78 
(C2'''), 50.00 (C1), 48.80 (C3), 40.29 (C6'''), 30.02 (C2), 22.95 (CH3). HRESIMS 
calcd for C29H56N5O19[M+H]+ , 778.3570; found, 778.3600.  
4’-O-β-D-Mannopyranosyl paramomycin (24β).  Compound 24β (11 mg, 33%) 
was obtained in the form of a white solid by hydrogenolysis general producedure 
C of 20β (68 mg) after Sephadex chromatography.  [α]RTD +31.9 (c 0.54, H2O); 1H 
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NMR (600 MHz, CDCl3) δ 5.57 (d, J = 4.0 Hz, 1 H: H1'), 5.20 (br s, 1 H: H1''), 
5.11 (s, 1 H: H1'''), 4.57 (s, 1H: H1''''), 4.35 (t, J = 5.5 Hz, 1 H: H3''), 4.20 (s, 1 H: 
H2''), 4.12 (s, 1 H: H5'''), 4.04 (s, 1 H: H3'''), 4.02 (s, 1 H: H4''), 3.87 (m, 2 H: H3', 
H2''''), 3.72-3.78 (m, 3 H: H6'''', H5', H5''), 3.57-3.70 (m, 7 H: H6', H6', H5, H4''', 
H4, H5'', H4'), 3.52-3.55 (dd, J = 6.6 Hz, 12.1 Hz, 1 H: H6''''), 3.43-3.47 (m, 2 H: 
H3'''', H6), 3.39 (s, 1 H: H2'''), 3.37 (t, J = 9.9 Hz, 1 H: H4''''), 3.16-3.28 (m, 4 H: 
H6''', H5'''', H6''', H2'), 3.07-3.11 (m, 2 H: H1, H3), 2.15 (m, 1 H: H2eq), 1.49 (m, 1 
H: H2ax). 13C NMR (151 MHz, CDCl3) δ 109.87 (C1''), 99.96 (C1''''), 95.61 (C1'), 
95.35 (C1'''), 84.64 (C5), 81.07 (C4''), 79.22 (C4), 77.79 (C4'), 76.39 (C5''''), 
74.98 (C3''), 73.28 (C2''), 72.86 (C3''''), 73.63 (C6), 72.01 (C5'), 70.38 (C2''''), 
70.15 (C5'''), 67.99 (C3'), 67.62 (C3'''), 67.19 (C4'''), 66.52 (C4''''), 60.84 (C6''''), 
59.91 (C5''), 59.56 (C6'), 53.61 (C2'), 50.76 (C2'''), 50.01 (C1), 48.83 (C3), 40.29 
(C6'''), 30.01 (C2), 23.00 (CH3). HRESIMS calcd for C29H56N5O19 [M+H]+ , 
778.3570; found, 778.3561. 
4’-O-α-D-Glucopyranosyl paramomycin (25α). Compound 25α (29 mg, 39%) 
was obtained as a white solid by hydrogenolysis general producedure C of 21α 
(120 mg) after Sephadex chromatography. [α]RTD +73.2 (c 0.50, H2O); 1H NMR 
(600 MHz, CDCl3) δ 5.59 (d, J = 4.0 Hz, 1 H: H1'), 5.21 (d, J = 3.0 Hz, 1H: H1''''), 
5.18 (br s, 1 H: H1''), 5.11 (s, 1 H: H1'''), 4.34 (t, J = 5.1 Hz, 1 H: H3''), 4.20 (s, 1 
H: H2''), 4.12 (s, 1 H: H5'''), 4.00-4.05  (m, 3 H: H3''', H3', H4''), 3.79 (t, J = 8.8 Hz, 
1 H: H5'), 3.63-3.76 (m, 7 H: H5'', H4, H5, H6'''', H6', H6', H4'''), 3.55-3.60 (m, 3 
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H: H5'', H6'''', H4'), 3.46-3.51 (m, 3 H: H3'''', H5'''', H6), 3.41-3.44 (dd, J = 3.7 Hz, 
9.9 Hz, 1 H: H2''''), 3.40 (s, 1 H: H2'''), 3.28 (dd, J = 4.0 Hz, 9.9 Hz, 1 H: H2'), 
3.22-3.26 (m, 3 H: H4'''',  H6''', H3), 3.16 (dd, J = 4.0 Hz, 14.0 Hz, 1 H: H2'), 3.22-
3.27 (m, 3 H: H3, H4'''', H6'''), 3.16-3.19 (dd, J = 4.0 Hz, 14.0 Hz, 1 H: H6'''), 3.13 
(dt, J = 3.6 Hz, 10.1 Hz, 1 H: H1), 2.23 (m, 1 H: H2eq), 1.60 (m, 1 H: H2ax). 13C 
NMR (151 MHz, CDCl3) δ 109.98 (C1''), 99.44 (C1''''), 95.26 (C1', C1'''), 84.64 
(C5), 81.07 (C4''), 79.22 (C4), 77.79 (C4'), 76.39 (C5''''), 74.98 (C3''), 73.28 (C2''), 
72.86 (C3''''), 73.63 (C6), 72.01 (C5'), 70.38 (C2''''), 70.15 (C5'''), 67.99 (C3'), 
67.62 (C3'''), 67.19 (C4'''), 66.52 (C4''''), 60.37 (C6'), 59.93 (C6'''', C5''), 53.29 
(C2'), 50.74 (C2'''), 49.78 (C1), 48.70 (C3), 40.29 (C6'''), 28.85 (C2), 23.05 (CH3). 
HRESIMS calcd for C29H56N5O19 [M+H]+ , 778.3570; found, 778.3594. 
4’-O-β-D-Glucopyranosyl paramomycin (25β). Compound 25β (9 mg, 87%) 
was obtained in the form of a white solid by hydrogenolysis general producedure 
C of 21β (17 mg) after Sephadex chromatography. [α]RTD +30.0 (c 0.45, H2O); 1H 
NMR (600 MHz, CDCl3) δ 5.59 (d, J = 3.7 Hz, 1 H: H1'), 5.19 (d, J = 2.9 Hz, 1 H: 
H1''), 5.09 (s, 1H: H1'''), 4.34 (t, J = 6.6 Hz, 1 H: H3''), 4.31 (d, J = 8.1 Hz, 1 H: 
H1''''), 4.19 (br s, 1 H: H2''), 4.12 (t, J = 4.4 Hz, 1 H: H5'''), 4.03 (t, J = 3.3 Hz, 1 H: 
H3'''), 4.01(m, 1 H: H4''), 3.82 (t, J = 10.6 Hz, 1 H: H3'), 3.77 (m, 1 H: H5''''), 3.72-
3.74 (m, 2 H: H6'''', H5''), 3.68 (dd, J = 4.1 Hz, 12.4 Hz, 1 H: H6''''), 3.62-3.65 (m, 
2 H: H5, H4'''), 3.59 (dd, J = 4.8 Hz, 12.5 Hz, 1 H: H5''), 3.52-3.57 (m, 4 H: H6', 
H4', H6', H6), 3.43 (t, J = 10.3 Hz, 1 H: H4), 3.37 (s, 1 H: H2'''), 3.31 (t, J = 9.1 Hz, 
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1 H: H3''''), 3.27 (dd, J = 2.4 Hz, 5.8 Hz, 1 H: H5'), 3.16-3.26 (m, 4 H: H6''', H4'''', 
H2', H6'''), 3.11 (t, J = 9.2 Hz, 1 H: H2''''), 2.99-3.07 (m, 2 H: H1, H3), 2.10 (dt, J = 
4.0 Hz, 12.5 Hz, 1 H: H2eq), 1.44 (m, 1 H: H2ax). 13C NMR (151 MHz, CDCl3) δ 
109.80 (C1''), 102.44 (C1''''), 95.80 (C1'), 95.44 (C1'''), 84.67 (C5), 81.03 (C4''), 
79.94 (C6), 77.73 (C4'), 75.90 (C5'), 75.38 (C3''''), 74.99 (C3''), 73.25 (C2''''), 
73.08 (C2''), 73.04 (C4), 72.14 (C5''''), 70.19 (C5'''), 69.33 (C4''''), 68.21 (C3'), 
67.71 (C3'''), 67.23 (C4'''), 60.46 (C5''), 59.96 (C6'), 59.93 (C6''''), 53.84 (C2'), 
50.82 (C2'''), 50.12 (C1), 48.93 (C3), 40.30 (C6'''), 30.55 (C2), 23.12 (CH3). 
HRESIMS calcd for C29H56N5O19 [M+H]+ , 778.3570; found, 778.3537.  
4’-O-α-D-Galactopyranosyl paramomycin (26α). Compound 26α (36 mg, 62%) 
was obtained as a white solid by hydrogenolysis general producedure C of 22α 
(100 mg) after Sephadex chromatography. [α]RTD +9.2 (c 0.45, H2O); 1H NMR 
(600 MHz, CDCl3) δ 5.59 (s, 1 H: H1'), 5.20 (s, 1H: H1''''), 5.16 (s, 1 H: H1''), 5.09 
(s, 1 H: H1'''), 4.32 (br s, 1 H: H3''), 4.19 (s, 1 H: H2''), 4.10 (s, 1 H: H5'''), 3.98-
4.05 (m, 3 H: H3''', H3', H4''), 3.80 (t, J = 10.3 Hz, 1 H: H4), 3.73-3.79 (m, 3 H: 
H5', H3'''', H5''''), 3.65-3.72 (m, 5 H: H5'', H6'''', H5, H2'''', H6''''), 3.60-3.64 (m, 2 
H: H4''', H4''''), 3.51-3.59 (m, 4 H: H6', H6', H5'', H4'), 3.48 (t, J  = 9.5 Hz, 1 H: 
H6), 3.38 (s, 1 H: H2'''), 3.29-3.34 (m, 2 H: H3, H2'), 3.22 (m, 1 H: H6'''), 3.11-
3.18 (m, 2 H: H6''', H1), 2.24-2.28 (m, 1 H: H2eq), 1.63 (m, 1 H: H2ax). 13C NMR 
(151 MHz, CDCl3) δ 110.01 (C1''), 99.66 (C1''''), 95.30 (C1'''), 95.11 (C1'), 84.19 
(C5), 81.22 (C4''), 77.43 (C4), 75.38 (C4'), 75.13 (C3''), 73.31 (C2''), 73.20 (C5'), 
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72.21 (C6), 71.89 (C5''''), 70.16 (C5'''), 69.13 (C4''''), 69.06 (C3''''), 68.83 (C3'), 
68.22 (C2''''), 67.56 (C3'''), 67.19 (C4'''), 61.15 (C6'), 60.03 (C5''), 59.97 (C6''''), 
53.17 (C2'), 50.78 (C2'''), 49.69 (C1), 48.68 (C3), 40.32 (C6'''), 28.27 (C2), 22.59 
(CH3).  HRESIMS calcd for C29H56N5O19 [M+H]+ , 778.3570; found, 778.3577. 
4’-O-β-D-Galactopyranosyl paramomycin (26β). Compound 26β (5.5 mg, 
39%) was obtained in the form of a white solid by hydrogenolysis general 
producedure C of 22β (24 mg) after Sephadex chromatography . [α]RTD +38.7 (c 
0.37, H2O); 1H NMR (600 MHz, CDCl3) δ 5.65 (s, 1 H: H1'), 5.23 (s, 1H: H1''), 
5.15 (s, 1 H: H1'''), 4.38 (s, 1 H: H3''), 4.31 (s, 1 H: H1''''), 4.23 (s, 1 H: H2''), 4.17 
(s, 1 H: H5'''), 4.05-4.10 (m, 2 H: H3''', H4''), 3.95 (t, J = 10.3 Hz, 1 H: H3'), 3.86 (t, 
J = 9.5 Hz, 1 H: H4), 3.69-3.84 (m, 6 H: H6'''', H5'''', H4'''',  H5'', H5, H6''''), 3.68 (s, 
1 H: H4'''), 3.56-3.67 (m, 4 H: H5'', H6', H5, H4', H6'), 3.50-3.57 (m, 3 H: H5', 
H3'''', H6), 3.45 (s, 1 H: H2'''), 3.32-3.40 (m, 3 H: H2'''', H3, H2'), 3.27-3.30 (br s, 1 
H: H6'''), 3.18-3.25 (m, 2 H: H1, H6'''), 2.34 (m, 1 H: H2eq), 1.68 (m, 1 H: H2ax).13C 
NMR (151 MHz, CDCl3) δ 109.97 (C1''), 102.82 (C1''''), 95.31 (C1'''), 95.18 (C1'), 
84.24 (C5), 81.21 (C4''), 77.27 (C4), 77.19 (C4'), 75.39 (C5'), 75.06 (C3''), 73.33 
(C2''), 72.94 (C5''''), 72.39 (C6), 72.22 (C3''''), 68.22 (C2''''), 70.11 (C5'''), 68.41 
(C4''''), 67.58 (C3'), 67.55 (C3'''), 67.19 (C4'''), 61.06 (C6'), 60.03 (C5''), 59.39 
(C6''''), 53.22 (C2'), 50.73 (C2'''), 49.63 (C1), 48.66 (C3), 40.31 (C6'''), 28.19 (C2), 
21.83 (CH3). HRESIMS calcd for C29H56N5O19 [M+H]+, 778.3570; found, 
778.3588.   
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4’-O-(4" " " "-Amino-4" " " "-deoxy-α-D-glucopyranosyl) paramomycin (27α). 
Compound 27α (20 mg, 64%) was obtained as a white solid by hydrogenolysis 
general producedure C of 23α (54 mg) after Sephadex chromatography . [α]RTD 
+53.8 (c 0.40, H2O); 1H NMR (600 MHz, CDCl3) δ 5.63 (s, 1 H: H1'), 5.32 (s, 1H: 
H1''''), 5.19 (s, 1 H: H1''), 5.11 (s, 1 H: H1'''), 4.34 (t, J = 5.5 Hz, 1 H: H3''), 4.21 (s, 
1 H: H2''), 4.12 (br s, 1 H: H5'''), 4.01-4.07  (m, 3 H: H3''', H3', H4''), 3.79-3.84 (m, 
2 H: H5'''', H4), 3.68-3.77 (m, 5 H: H5'', H4, H6'''', H6', H3''''), 3.57-3.66 (m, 6 H: 
H5'', H6', H6'''', H4', H4''', H5), 3.49-3.54 (m, 2 H: H2'''', H6), 3.41 (s, 1 H: H2'''), 
3.30-3.39 (m, 2 H: H3, H2'), 3.24 (dd, J = 6.6 Hz, 13.9 Hz, 1 H: H6'''), 3.15-3.20 
(m, 2 H: H1, H6'''), 3.07 (t, J = 10.6 Hz, 1 H: H4''''), 3.13 (dt, J = 3.6 Hz, 10.1 Hz, 
1 H: H1), 2.29 (m, 1 H: H2eq), 1.66 (m, 1 H: H2ax). 13C NMR (151 MHz, CDCl3) δ 
110.03 (C1''), 99.66 (C1''''), 95.29 (C1'''), 95.25 (C1'), 84.24 (C5), 81.20 (C4''), 
77.18 (C4), 75.15 (C3''), 75.13 (C4'), 73.31 (C2''), 72.68 (C5'), 72.20 (C2''''), 
71.22 (C6), 70.10 (C5'''), 69.03 (C5''''), 68.93 (C3''''), 68.81 (C3'), 67.53 (C3'''), 
67.18 (C4'''), 60.24 (C6'), 59.94 (C5''), 59.89 (C6''''), 53.31 (C2'), 52.08 (C4''''), 
50.73 (C2'''), 49.63 (C1), 48.61 (C3), 40.30 (C6'''), 28.15 (C2), 21.74 (CH3). 
HRESIMS calcd for C29H57N6O18 [M+H]+, 777.3729; found, 777.3718. 
4’-O-(4" " " "-Amino-4" " " "-deoxy-β-D-glucopyranosyl) paramomycin (27β). 
Compound 27β (5 mg, 29%) was obtained as a white solid by hydrogenolysis 
general producedure C of 23β (22 mg) after Sephadex chromatography. [α]RTD 
+66.86 (c 0.17, H2O); 1H NMR (600 MHz, CDCl3) δ 5.66 (s, 1 H: H1'), 5.25 (s, 1 
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H: H1''), 5.16 (s, 1H: H1'''), 4.42-4.47 (m, 2 H: H1'''', H3''), 4.24 (s, 1 H: H2''), 4.17 
(s, 1 H: H5'''), 4.07-4.10 (m, 2 H: H3''', H4''), 3.94 (br s, 1 H: H3'), 3.88 (br s, 1 H: 
H4), 3.73-3.84 (m, 7 H: H5', H5, H5'', H6', H6'''', H6'''', H6'), 3.69 (s, 1 H: H4'''), 
3.59-3.66 (m, 3 H: H5'''', H4', H5''), 3.54-3.58 (m, 2 H: H3'''', H6), 3.46 (s, 1 H: 
H2'''), 3.40 (br s, 1 H: H3) 3.35 (br s, 1H: H2'), 3.15-3.31 (m, 4 H: H6''', H2'''', H6''', 
H1), 3.12 (t, J = 10.6 Hz, 1 H: H4''''), 3.13 (dt, J = 3.6 Hz, 10.1 Hz, 1 H: H1), 2.33 
(m, 1 H: H2eq), 1.70 (m, 1 H: H2ax). 13C NMR (151 MHz, CDCl3) δ 110.01 (C1''), 
102.45 (C1''''), 95.42 (C1'''), 95.35 (C1'), 84.27 (C5), 81.20 (C4''), 77.50 (C4), 
77.36 (C4'), 75.26 (C3''), 73.44 (C2''''), 73.42 (C2''), 72.98 (C5'), 72.28 (C5''''), 
72.22 (C3''''), 71.74 (C6), 70.19 (C5'''), 67.59 (C3'), 67.56 (C3'''), 67.28 (C4'''), 
60.32 (C6'), 60.03 (C5''), 59.37 (C6''''), 53.38 (C2'), 52.18 (C4''''), 50.84 (C2'''), 
49.70 (C1), 48.75 (C3), 40.40 (C6'''), 28.22 (C2), 21.47 (CH3). HRESIMS calcd 
for C29H57N6O18 [M+H]+, 777.3729; found, 777.3704. 
 (2,3,4,6-Tetra-O-(p-methyl benzyl)-α-D-glucopyranosyl) dibutyl phosphate 
(33).  
O
O
O
O
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(2,3,4,6-Tetra-O-benzylmethyl-β-D-glucopyranosyl) thioglycoside (270 mg, 1 eq), 
dibutyl phosphate (233 ul, 3 eq) and Acid Washed Molecular Sieves 3 Å (AW-MS 
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300) was stirred  in anhydrous DCM at room temperature for 1.5 h and then 
cooled to 0 ˚C. 185 mg NIS was added (2.1 eq) followed by a catalytic amount of 
TfOH. The solution was turned to red color from brown color. It was stirred at 0 
˚C for 1.5 h before quenched with Hunig’s base. The molecular sieves were 
filtered out. The obtained filtrate was washed with sat. Na2S2O3 three times. The 
organic layer was then condensed and subject to silica gel chromatography 
(Hexanes: EtOAc=3:1, Rf=0.27). 250 mg white solid product (yield: 81%) was 
obtained. [α]RTD -25.3 (c 0.29, CHCl3); 1H NMR (500 MHz, CDCl3)  δ 7.10-7.40 (m, 
20 H, aromatic),  5.91 (dd, J = 3.4 Hz, 7.0 Hz, 1 H: H1), 4.40-4.92 (m, 8 H: 
PhCH2), 3.97-4.07 (m, 4 H: PO2(OCH2CH2CH2CH3)2), 3.94 (d, J = 9.5 Hz, 1 H: 
H5), 3.91(t, J = 9.5 Hz, 1 H: H3), 3.71-3.73 (dd, J = 3.7 Hz, 11.0 Hz, 1 H: H6), 
3.66-3.70 (t, J = 9.8 Hz, 1 H: H4), 3.58-3.61 (m, 2 H: H2, H6'), 2.34 (m, 12 H: 
OBnCH3), 1.55-1.66 (m, 4 H: PO2(OCH2CH2CH2CH3)2), 1.27-1.39 (m, 4 H: 
PO2(OCH2CH2CH2CH3)2), 0.90 (t, J = 7.3 Hz, 3 H: PO2(OCH2CH2CH2CH3)), 0.87 
(t, J = 7.6 Hz, 3 H: PO2(OCH2CH2CH2CH3)); 13C NMR (125 MHz, CDCl3)  δ 95.22 
(C1), 81.07 (C3), 77.80 (C2), 77.27 (C4), 72.72 (C5), 67.67 (C6), 67.79 
(PO2(OCH2CH2CH2CH3)), 67.42 (PO2(OCH2CH2CH2CH3)), 32.18 
(PO2(OCH2CH2CH2CH3)), 32.14 (PO2(OCH2CH2CH2CH3)), 21.17 (OBnCH3), 
18.63 (PO2(OCH2CH2CH2CH3)), 18.57 (PO2(OCH2CH2CH2CH3)), 13.60 
(PO2(OCH2CH2CH2CH3)2); PhCH2 (4 C: 75.49, 75.01, 73.33, 72.36 ); HR ESI MS 
calcd for C46H61O9NaP [M+Na]+ , 811.3951; found, 811.3979. 
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(2,3,4,6-Tetra-O-benzyl-α-D-mannopyranosyl) dibutyl phosphate (34α).  
DCM, -10°C, 3h, AW-MS 300, 69%
O
OBnBnO
BnO
BnO
SPh
(BuO)2PO2H (3 eq), NIS (2.1 eq), cat. TfOH
O
OBnBnO
BnO
BnO
O
P
OBuBuO
O
34α  
(2,3,4,6-Tetra-O-benzyl-α-D-mannopyranosyl) thioglycoside (50 mg, 1 eq), 
dibutyl phosphate (48 ul, 3 eq) and acid washed molecular sieves 3 Å (AW-MS 
300) was stirred  in anhydrous DCM at room temperature for 1 h and then cooled 
to -10 ˚C. 37 mg NIS was added (2.1 eq) followed by a catalytic amount of TfOH. 
The solution was turned to a red color from brown color. It was stirred at -10 ˚C 
for 3 h before quenched with Hunig’s base. The molecular sieves were filtered 
out. The obtained filtrate was washed with sat. Na2S2O3 three times. The organic 
layer was then condensed and subject to silica gel chromatography (Hexanes: 
EtOAc=3:1, Rf=0.3). 40 mg white solid was obtained (yield: 69%). It is a pure α 
anomer. [α]RTD +48.0 (c 0.20, CH2Cl2); 1H NMR (600 MHz, CDCl3)  δ 7.10-7.40 
(m, 20 H, aromatic),  5.75 (d, J = 6.2 Hz, 1 H: H1), 4.49-4.90 (m, 8 H: PhCH2), 
3.71 (t, J = 9.5 Hz, 1 H: H4), 3.89-4.03 (m, 6 H: PO2(OCH2CH2CH2CH3)2, H3, 
H5), 3.83 (br s, 1 H: H2), 3.78-3.81 (dd, J = 4.8 Hz, 11.0 Hz, 1 H: H6), 3.70 (d, J 
= 11.0 Hz, 1 H: H6'), 1.57 (m, 4 H: PO2(OCH2CH2CH2CH3)2), 1.33 (m, 4 H: 
PO2(OCH2CH2CH2CH3)2), 0.90 (t, J = 7.3 Hz, 3 H: PO2(OCH2CH2CH2CH3)), 0.80 
(t, J = 7.0 Hz, 3 H: PO2(OCH2CH2CH2CH3)); 13C NMR (151 MHz, CDCl3)  δ 95.85 
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(C1), 78.85 (C3), 74.58 (C2), 74.21 (C4), 73.82 (C5), 68.81 (C6), 67.74 
(PO2(OCH2CH2CH2CH3)), 67.64 (PO2(OCH2CH2CH2CH3)), 32.20 
(PO2(OCH2CH2CH2CH3)), 32.13 (PO2(OCH2CH2CH2CH3)), 18.60 
(PO2(OCH2CH2CH2CH3)), 18.51 (PO2(OCH2CH2CH2CH3)), 13.57 
(PO2(OCH2CH2CH2CH3)), 13.55 (PO2(OCH2CH2CH2CH3)); PhCH2 (4 C: 75.20, 
73.42, 72.72, 72.23); HR ESI MS calcd for C42H53O9NaP [M+Na]+ , 755.3325; 
found, 755.3293. 
 (2,3,4,6-Tetra-O-benzyl-β-D-mannopyranosyl) dibutyl phosphate (34β).  
OBnOBnO
BnO
OBn
SPh
TTBP (3 eq), DPSO (1.2 eq),
Tf2O (1.2 eq), H2O in THF, 3 Å MS
-78 °C for 30 min in DCM,
 90%
OBnOBnO
BnO
OBn
OH
OBnOBnO
BnO
OBn
O P
O
BuO
OBu
THF, -78°C, 1h
MS 3Å
(BuO)2PCl (1eq)
NaH (1eq)
34β  
A 1 ml anhydrous DCM solution of (2,3,4,6-Tetra-O-benzyl-α-D-mannopyranosyl) 
thioglycoside (40 mg, 1 eq), DPSO (19 mg, 1.2 eq), TTBP (60 mg, 3 eq) and  
activated 3 Å molecular sieves was stirred at R.T. for 3 hours before cooled down 
to -78 ˚C. Tf2O (16 ul, 1.2 eq) was added  slowly to the solution to activate the 
donor. After the solution was stirred for 30 min, a solution of dI H2O (10 eq) in 
THF was added. The resulting solution was stirred at the low temperature for 0.5 
hours before quenched by Sat. NaHCO3. It was then diluted by EtOAc and the 
organic phase was washed with Sat. NaHCO3 three times. The organic layer was 
then dried over Na2SO4, concentrated and subjected to column chromatography 
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(Hexanes: EtOAc=1:1, Rf=0.3). 31 mg product (yield: 90%) was obtained. It is a 
white sticky solid. 25 mg product (1 eq) was dissolved in anhydrous THF and 
stirred with activated 3 Å molecular sieves at room temperature for 1 h. 3.6 mg 
NaH (2.5 eq)  was added. The solution was then cooled down to -78 ˚C. 31 ul 
(BuO)2PO2Cl (2.5 eq) was added slowly. The reaction was allowed to stir at -78 
˚C before being quenched by sat. NaHCO3. It was washed with brine and 
concentrated for column chromatography (Hexanes: EtOAc=4:1 Rf=0.2). The 
white sticky solid got is β anomer as expected. [α]RTD +18.6 (c 1.32, CHCl3); 1H 
NMR (600 MHz, CDCl3)  δ 7.10-7.40 (m, 20 H, aromatic),  5.21 (d, J = 7.3 Hz, 1 
H: H1), 4.48-4.92 (m, 8 H: PhCH2), 3.94-4.08 (m, 6 H: PO2(OCH2CH2CH2CH3)2, 
H2, H5), 3.73-3.77 (m, 2 H: H6', H6), 3.50-3.57 (m, 2 H: H3, H4), 1.59-1.64 (m, 4 
H: PO2(OCH2CH2CH2CH3)2), 1.31-1.38 (m, 4 H: PO2(OCH2CH2CH2CH3)2), 0.90 
(t, J = 7.3 Hz, 3 H: PO2(OCH2CH2CH2CH3)), 0.80 (t, J = 7.3 Hz, 3 H: 
PO2(OCH2CH2CH2CH3)); 13C NMR (151 MHz, CDCl3)  δ 96.79 (C1), 81.70 (C3), 
76.17 (C5), 74.70 (C2), 74.09 (C4), 69.13 (C6), 68.10 (PO2(OCH2CH2CH2CH3)), 
67.84 (PO2(OCH2CH2CH2CH3)), 32.22 (PO2(OCH2CH2CH2CH3)), 32.18 
(PO2(OCH2CH2CH2CH3)), 18.63 (PO2(OCH2CH2CH2CH3)), 18.60 
(PO2(OCH2CH2CH2CH3)), 13.62 (PO2(OCH2CH2CH2CH3)), 13.58 
(PO2(OCH2CH2CH2CH3)); PhCH2 (4 C: 75.10, 74.34, 73.37, 71.96); HR ESI MS 
calcd for C42H53O9NaP [M+Na]+ , 755.3325; found, 755.3289. 
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(2,3,4,6-Tetra-O-benzyl-α-D-glucopyranosyl) dibutyl phosphate (35α).  
O
OBn
BnO
BnO
BnO
35α:35β=1:1
O
OBn
BnO
BnO
BnO
 (BuO)2PO2H (3 eq), 4 °C, 10 min in DCM
cat. TfOH, NIS (1.05 eq), AW-MS 300, 90%
SPh O P
O
BuO
OBu
 
(2,3,4,6-Tetra-O-benzyl-β-D-glucopyranosyl) thioglycoside (100 mg, 1 eq), dibutyl 
phosphate (94 ul, 3 eq) and acid washed molecular sieves 3 Å (AW-MS 300) was 
stirred  in anhydrous DCM at room temperature for 1 h and then cooled to 4 ˚C. 
38 mg NIS was added (1.05 eq) followed by a catalytic amount of TfOH. The 
solution was turned to a red color from brown color. It was stirred at 4 ˚C for 10 
min before quenched with Hunig’s base. The molecular sieves were filtered out. 
The obtained filtrate was washed with sat. Na2S2O3 three times. The organic 
layer was then condensed and subject to silica gel chromatography (Hexanes: 
EtOAc=3:1, Rf=0.26). 104 mg white solid was obtained (yield: 90%). It is a 
mixture of α, β anomers (α: β=1:1).  It was then subjected to gradient Reverse 
Phase-HPLC purification (acetonitrile: H2O 80:20 to 90:10) to get the isolated 
anomers. [α]RTD +44.4 (c 0.068, CH2Cl2); 1H NMR (500 MHz, CDCl3)  δ 7.10-7.40 
(m, 20 H, aromatic),  5.91 (dd, J = 3.4 Hz, 7.3 Hz, 1 H: H1), 4.47-4.98 (m, 8 H: 
PhCH2), 3.98-4.07 (m, 5 H: PO2(OCH2CH2CH2CH3)2, H5), 3.98 (t, J = 9.1 Hz, 1 
H: H3), 3.75-3.78 (dd, J = 3.7 Hz, 10.7 Hz, 1 H: H6), 3.73 (t, J = 9.5 Hz, 1 H: H4), 
3.63-3.66 (m, 2 H: H2, H6'), 1.59 (m, 4 H: PO2(OCH2CH2CH2CH3)2), 1.33 (m, 4 H: 
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PO2(OCH2CH2CH2CH3)2), 0.90 (t, J = 7.3 Hz, 3 H: PO2(OCH2CH2CH2CH3)), 0.80 
(t, J = 7.6 Hz, 3 H: PO2(OCH2CH2CH2CH3)); 13C NMR (125 MHz, CDCl3)  δ 95.09 
(C1), 81.18 (C3), 79.35 (C2), 77.25 (C4), 72.84 (C5), 67.75 (C6), 68.10 
(PO2(OCH2CH2CH2CH3)), 67.42 (PO2(OCH2CH2CH2CH3)), 32.18 
(PO2(OCH2CH2CH2CH3)), 32.14 (PO2(OCH2CH2CH2CH3)), 18.62 
(PO2(OCH2CH2CH2CH3)), 18.55 (PO2(OCH2CH2CH2CH3)), 13.59 
(PO2(OCH2CH2CH2CH3)), 13.57 (PO2(OCH2CH2CH2CH3)); PhCH2 (4 C: 75.64, 
75.18, 73.51, 72.38); HR ESI MS calcd for C42H53O9NaP [M+Na]+ , 755.3325; 
found, 755.3290. 
(2,3,4,6-Tetra-O-benzyl-β-D-glucopyranosyl) dibutyl phosphate (35β). [α]RTD -
10.4 (c 0.09, CHCl3); 1H NMR (600 MHz, CDCl3)  δ 7.10-7.40 (m, 20 H, aromatic),  
5.16 (t, J = 7.3 Hz, 1 H: H1), 4.48-4.89 (m, 8 H: PhCH2), 3.90-4.10 (m, 4 H: 
PO2(OCH2CH2CH2CH3)2), 3.73 (dd, J = 3.6 Hz, 11.0 Hz, 1 H: H6), 3.71 (t, J = 8.8 
Hz, 1 H: H4), 3.69 (m, 1 H: H6'), 3.66 (t, J = 8.8 Hz, 1 H: H3), 3.55 (d, J = 9.5 Hz, 
1 H: H5), 3.53 (t, J = 8.4 Hz, 1 H: H2),1.61 (quintet, J = 7.0 Hz, 2 H: 
PO2(OCH2CH2CH2CH3)), 1.55 (quintet, J = 7.0 Hz, 2 H: PO2(OCH2CH2CH2CH3)), 
1.33-1.37 (sextet, J = 7.7 Hz, 2 H: PO2(OCH2CH2CH2CH3)), 1.24-1.31 (sextet, J 
= 7.7 Hz, 2 H: PO2(OCH2CH2CH2CH3)), 0.88 (t, J = 7.3 Hz, 3 H: 
PO2(OCH2CH2CH2CH3)), 0.84 (t, J = 7.6 Hz, 3 H: PO2(OCH2CH2CH2CH3)); 13C 
NMR (150 MHz, CDCl3)  δ 98.85 (C1), 84.35 (C3), 82.02 (C2), 77.24 (C4), 75.37 
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(C5), 68.47 (C6), 67.70 (PO2(OCH2CH2CH2CH3)), 67.66 
(PO2(OCH2CH2CH2CH3)), 32.16 (PO2(OCH2CH2CH2CH3)), 32.12 
(PO2(OCH2CH2CH2CH3)), 18.59 (PO2(OCH2CH2CH2CH3)), 18.51 
(PO2(OCH2CH2CH2CH3)), 13.55 (PO2(OCH2CH2CH2CH3)), 13.50 
(PO2(OCH2CH2CH2CH3)); PhCH2 (4 C: 75.64, 75.18, 74.98, 74.78); HR ESI MS 
calcd for C42H53O9NaP [M+Na]+ , 755.3325; found, 755.3319. 
In-source Fragmentation of Glycosyl Phosphates: 
The mass spectrometric study was carried out using a Waters LCT Permiere Xe 
TOF mass spectrometer. The spectra were recorded in positive ion mode with a 
source temperature of 120 oC using a desolvation gas flow of 800 L/h. Samples 
were dissolved in an sodium acetate methanolic solution ([NaOAc]=0.18 mM). 
The sodium acetate methanolic solution was prepared by adding 750 µl aqueous 
NaOAc solution ([NaOAc]=12.20 mM) to 50 ml methanol. Ions were detected 
using the broadband detection mode covering a mass range from 20 to 1000 
amu. For each sample, the compound was dissolved in ethyl acetate solvent first 
to make a 0.508 mM solution considering that the compounds doesn’t dissolve 
well in methanol solution directly. 2 µl of this kind of ethyl acetate solution of a 
interested glycosyl phosphate sample and 2 µl of this kind of ethyl acetate 
solution of internal standard phosphate sample was then added to 1 ml sodium 
acetate methanolic solution. It was then mixed thoroughly before injecting to the 
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mass spactrometer. A 2 µl methanol solution of the phosphate was infused into 
the ESI-MS source at room temperature. The in-source fragmentation study of 
the glycosyl phosphate was carried by increasing cone voltages starting from 
40V with an incremental change in cone voltage till 2% fragmentation of standard 
phosphate was observed. Each fragmentation experiment was duplicated for 
three times.  
Data processing from the Mass Spectrum obtained In-source 
Fragmentation Experiment:  
 Table 8 shows the direct reading of relative abundance of all the 
fragment ions and interested glycosyl phosphate parental ion to internal standard 
parental ion from the mass spectrum of cone voltage fragmentation experiment. 
CV stands for the cone voltage at which internal standard reached approximately 
2% fragmentation. RA1 and RA2 are the relative abundance of daughter ions of 
interested glycosyl phosphate to internal standard parental ion. RA1 belongs to 
the daughter ion lost both phosphoric acid and one benzyl group in fragmentation. 
RA2 belongs to the daughter ion lost only phosphoric acid. RA3 is the relative 
abundance of daughter ion of internal standard to internal standard parental ion 
itself. RA4 is the relative abundance of interested glycosyl phosphate parental ion 
to internal standard parental ion. 
 Table 9 shows the processed data from Table 8. Rs is the relative 
abundance of daughter ion of internal standard to internal standard parental ion 
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itself. It’s the same value as RA3. RM1 and RM2 are the relative abundance of 
daughter ions of interested glycosyl phosphate to interested glycosyl phosphate 
parental ion itself. RM1=RA1/RA4; RM2=RA2/RA4. RM is the total relative 
abundance of daughter ions of interested glycosyl phosphate to interested 
glycosyl phosphate itself. RM=RM1+RM2. Relative stability value (RSV) is 
calculated as RSV=RM/Rs. The data shown in Table 6 are the averages of 3 
times duplicate experiments 
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Compound CV RA1 RA2 RA3 RA4 
34α 
155 0.00  16.13  2.24  71.18  
155 0.00  17.23  2.49  72.41  
155 1.24  15.94  2.29  70.94 
34β 
155 0.00  5.57  2.05  76.05 
155 0.00  6.16  2.82  77.73 
155 0.00  5.52  2.02  74.87 
35α 
155 0.00  7.22  2.41  92.74 
155 0.00  6.88  2.27  93.70 
155 0.00  6.98  2.52  93.27 
35β 
154 1.09  20.95  2.08  72.98  
154 0.00  19.95  2.15  72.17  
154 1.10  20.24  2.67  73.45  
36α 
151 12.07  16.74  2.17  27.41 
151 12.41  16.71  2.29  28.15 
151 12.50  16.41  2.44  26.98 
36β 
152 2.91  3.09  2.12  77.90 
152 3.21  3.20  2.42  76.13 
152 2.97  3.26  2.28  74.67 
37α 
150 4.81  5.93  2.25  57.08 
150 4.46  6.15  2.21  59.41 
150 5.42  5.58  2.34  57.12 
37β 
150 11.93  16.98  2.43  34.36 
150 12.12  16.91  2.42  34.51 
150 11.86  16.86  2.44  33.73 
Table 8. Relative abundance of all the fragment ions and interested 
glycosyl phosphate parental ion to internal standard parental ion. 
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Compound CV Rs RM1 RM2 RM RSV 
34α 
155 2.24  0.00 22.66 22.66 10.12  
155 2.49  0.00 23.80 23.80 9.56  
155 2.29  1.75 22.47 24.22 10.58  
34β 
155 2.05  0.00 7.32 7.32 3.57  
155 2.82  0.00 7.92 7.92 2.81  
155 2.02  0.00 7.37 7.37 3.65  
35α 
155 2.41  0.00 7.79 7.79 3.23  
155 2.27  0.00 7.34 7.34 3.23  
155 2.52  0.00 7.48 7.48 2.97  
35β 
154 2.08  1.49 28.71 30.20 14.52  
154 2.15  0.00 27.64 27.64 12.86  
154 2.67  1.50 27.56 29.05 10.88  
36α 
151 2.17  44.04 61.07 105.11 48.44  
151 2.29  44.09 59.36 103.45 45.17  
151 2.44  46.33 60.82 107.15 43.92  
36β 
152 2.12  3.74 3.97 7.70 3.63  
152 2.42  4.22 4.20 8.42 3.48  
152 2.28  3.98 4.37 8.34 3.66  
37α 
150 2.25  8.43 10.39 18.82 8.36  
150 2.21  7.51 10.35 17.86 8.08  
150 2.34  9.49 9.77 19.26 8.23  
37β 
150 2.43  34.72 49.42 84.14 34.62  
150 2.42  35.12 49.00 84.12 34.76  
150 2.44  35.16 49.99 85.15 34.90  
Table 9. Processed data in cone voltage fragmentation experiment 
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 The data in this thesis is trying to address two problems. The first problem 
is paromomycin associated ototoxicity; the second problem is the lack of precise 
reactivity data of glycosyl donors in one-pot synthesis. 
 Paromomycin is out of the market as an antibiotic due to its ototoxicity. 
Previous work done by Vasella and Böttger's groups identified 4'-O position of 
paromomycin as a promising site of modification to reduce the side effect. A 
series of 4'-O-glycopyranosyl paromomycin has been synthesized and tested for 
their biological activity and selectivity. From the results of anti bacterial ribosomal 
activity, anti hybrid ribosomal activity and antibacterial activity, it was found that 
4’-O-4-amino-α-D-glucopyranosyl paromomycin is the most active among the 
sixteen 4'-O-glycosyl paromomycin derivatives synthesized. However, 4’-O-4-
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amino-α-D-glucopyranosyl paromomycin shows an inability to differentiate 
eukaryotic ribosomal A site from prokaryotic ribosomal A site. 4’-O-glycosyl 
paromomycin derivatives with equatorially oriented glycosidic bond at the 4’-O-
glycosyl ring has more selectivity toward mitochondrial hybrid ribosomes than 
their corresponding derivatives with axially oriented glycosidic bonds. Therefore, 
it is promising to introduce an equatorially oriented substituent to the 4'-O 
position of paromomycin in the future drug design to reduce ototoxicity. 
 To evaluate the relative reactivity of glycosyl phosphate donors as a 
function of stereochemistry and protecting groups, electrospray ionization mass 
spectrometric fragmentation experiments were performed. Two methods to 
quantitatively access relative stability of glycosyl phosphates have been used: 
cone voltage fragmentation experiment and collision induced dissociation. 
Results from both methods showed that the α anomers of glucosyl phosphates 
are more stable than their corresponding β anomers regardless the protecting 
group. In the contrary, the α anomers of mannosyl phosphates are less stable 
than their corresponding β anomers irrespective with the protecting group. So it's 
likely glycosyl phosphates with the C1-dibutyl phosphate bond syn to the C2-H 
bond dissociate through a McLafferty rearrangement, but glycosyl phosphates 
with the C1-dibutyl phosphate bond anti to C2-H bond dissociate through an 
oxocarbenium ion. Cone voltage fragmentation experiment gave results 
contradicting the well-known benzylidene effect. Therefore, it seems the relative 
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stability of glycosyl phosphates cannot reflect their relative reactivity in 
glycosylation reaction. 
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